СПРАВКА
за
ЦИТИРАНИТЕ ПУБЛИКАЦИИ

до 30.06.2019

на доц. д-р Ирена Манолова Манолова, дм

катедра " Молекуляна биология, имунология и медицинска генетикаМФ
при Тракийски Университет, гр. Стара Загора

Цитирани публикации и брой на цитиранията

	Публикация	Чуждестранно списание (IF)	Моногра-фии	Дисерта-ции	Българско списание	Общо
1	**Публикация № 2** **MANOLOVA I.,** M. Dancheva, K. Halacheva. Predominance of IgG1 and IgG3 subclasses of antibodies to neutrophil cytoplasmic antigens in patients with systemic lupus erythematosus. ***Rheumat. Int***., 2002, 21:227-233	11 (9)	2			**13**
2	**Публикация № 3** **МАНОЛОВА И.**, К. Халачева, М Данчева. Проучване на антитела срещу цитоплазмени антигени на неутрофилите (АНЦА) при болни със системен лупус еритематодес (СЛЕ). ***Българска Медицина*** 2002, том X,бр.1:10-12				3	**3**
3	**Публикация № 7** **МАНОЛОВА И.**, И. Алтънкова, М. Огнянов. Клинично занчение на антителата срещу неутрофилни цитоплазмени съставки. Съвременна медицина, год.XLII, кн. 7, 4-7, 1991				1	**1**
4	**Публикация № 10** Halacheva K., **I. MANOLOVA**, D. Petkov, A. Andreev. Study of antineutrophil cytoplasmic antibodies in thromboangiitis obliterans (Buerger's disease). ***Scand. J. Immunol***., 48, 5, 544-550, 1998.	19 (11)	1			**20**
5	**Публикация № 11** **MANOLOVA I**, Dancheva M, Halacheva K. Anti-neutrophil cytoplasmic	36 (23)	3	1		**40**

	Публикация	Чуждестранно списание (IF)	Моногра-фии	Дисерта-ции	Българско списание	Общо
	antibodies in patients with systemic lupus erythematosus: Prevalence, antigen specificity and clinical associations. ***Rheumat Int***, 2001,20:197-200					
6	**Публикация № 12** Halacheva K, Gulubova M, **MANOLOVA I.,** and Petkov D. Expression of ICAM-1, VCAM-1, E-selectin and TNF-α on the endothelium of femoral and iliac arteries in thromboangiitis obliterans. ***Acta histochem,*** 2002,104:177-184	36 (25)	4	1		**41**
7	**Публикация № 13** **MANOLOVA IM**, Dancheva M. Antineutrophil cytoplasmic antibodies (ANCA) in patients with systemic sclerosis**.** ***J Rheumatol***, 2003, 30: 2078-79	2 (1)				**2**
8	**Публикация № 14** **MANOLOVA I**., M. Dantcheva. Antineutrophil cytoplasmic antibodies (ANCA) in Bulgarian patients with rheumatoiod artritis: Characterization and clinical associations**.** ***Rheumat Int***, 2005, 26(2):107-14.	12 (5)		1		**13**
9	**Публикация № 15** Gulubova M, **MANOLOVA I**, Vlaykova T, Prodanova M, Jovchev J. Adhesion molecules in chronic ulcerative cilitis. ***Intern J Colorectal Dis*** 2007 Jun;22(6):581-9.	21 (16)		1		**22**
10	**Публикация № 16** Gulubova MV, Vlaykova TI, **MANOLOVA IM**, Hadjipetkov PB, Popharitov AI. Implication of adhesion molecules in inflammation of the common bile duct in patients with secondary acute and chronic cholangitis due to biliary obstruction**.** ***Hepatogastroenterology*** 2008; 55:840-845	4 (3)	1			**5**
11	**Публикация № 17** Gulubova M, **MANOLOVA I,** Cirovski G, Sivrev D. Recruitment of dendritic cells in human liver with metastases. ***Clin Exp Metastasis*** (2008) 25:777-785	5 (5)	1			**6**
12	**Публикация № 18** **MANOLOVA IM**. Anti-Lactoferrin antoibodies in patients with connective tissue diseases. ***Folia Medica,*** 2003;45(4): 25-30	3 (1)		1		**4**
13	**Публикация № 28** **МАНОЛОВА И**., М. Иванова, С. Димитрова. Диагностична стойност					**1**

	Публикация	Чуждестранно списание (IF)	Монографии	Дисертации	Българско списание	Общо
	на АНА теста върху НЕр-2 при системните заболявания на съединителната тъкан. ***Ревматология*** XII, 2004, бр.2-3:47-51.			1		
14	**Публикация № 32** Иванова И., **И. МАНОЛОВА** и Р. Стоилов. Феномен на Raynaud и антицентромерни антитела: преглед на литературата и описание на два случая. Ревматология XIII, 2005, бр.2:27-31.		1		2	**3**
15	**Публикация № 35** **МАНОЛОВА И**., М. Иванова, С. Владева. Диагностична стойност на ANCA теста в клиничната практика. Ревматология XVI, 2008, бр.3-4:23-29.				1	**1**
16	**Публикация № 36** Иванова М., **И. МАНОЛОВА**, Р. Стоилов Сравнителна стойност на СУЕ и С – реактивния протеин в оценката на болестната активност при анкилозиращия спондилит. Ревматология XVI, 2008, бр.3-4:46-52.				1	**1**
17	**Публикация № 40** **МАНОЛОВА И.** Честота и антигенни специфичности на антинуклеарните антитела (АНА) в клиничната практика – анализ за периода 1998-2002. ***Съвременна медицина*** LV, 2004, бр.6:42-28			1		**1**
18	**Публикация № 41** **МАНОЛОВА И**., В. Цонева, М. Иванова. Сравнителна оценка на два имунометрични метода за определяне на антинуклеарни антитела (АНА). Медицински преглед, 2006, 42 (1) 98-101.				1	**1**
19	**Публикация № 42** Гълъбова М, **МАНОЛОВА И**, Влайкова Т. Имунохистохимично изследване на дендритни клекти при първичен хепатоцелуларен карцином. ***Съвременна медицина*** LVII, 2006, кн. 5:3-11.				1	**1**
20	**Публикация № 48** Gulubova M, **MANOLOVA I**, Kyurkchiev D, Julianov A, Altunkova I. Decrease in intrahepatic CD56+ lymphocytes in gastric and colorectal cancer patients with liver metastases. ***APMIS*** 2009;117(12):870-879.	32 (21)	1	2		**35**
21	**Публикация № 49** Gulubova M, **MANOLOVA I**, Ananiev J, Julianov A, Yovchev Y, Peeva K. Role of TGF-β1, its receptor TGFβRII and Smad proteins in the	40 (31)	1	1		**42**

	Публикация	Чуждестранно списание (IF)	Моногра-фии	Дисерта-ции	Българско списание	Общо
	progression of colorectal cancer. ***Int J Colorectale Disease*** 2010; 25(5):591-599					
22	**Публикация № 50** Ananiev J. R, M. V. Gulubova, **I. M. MANOLOVA**. Prognostic significance of CD83 positive tumor-infiltrating dendritic cells and expression of TGF-beta 1 in human gastric cancer. ***Hepatogastroenterology*** 2011; 58(110-111):1834-1840	21 (13)	1	1		**23**
23	**Публикация № 51** Ananiev J, Gulubova M, **MANOLOVA I,** Tchernev G. Prognostic significance of Her2/Neu expression in gastric cancer. ***Wien Klin Wochenschr***. 2011; 123(13-14):450-454	13(7)	3			**16**
24	**Публикация № 52** Ananiev J, Gulubova M, Tchernev G, Penkova M, Miteva R, Julianov A, **MANOLOVA I**. Relation between Transforming Growth Factor-B1 expression, its receptor and clinicopathological factors and survival in HER2-negative gastric cancers. ***Wien Klin Wochenschr.*** 2011; 123(21-22):668-673.	13 (10)				**13**
25	**Публикация № 53** Stoilov R, Ivanova M, Garbeva K, Marinova N, **MANOLOVA I**, Kalitchin ZH. Evaluation of lubrication and friction in knee joint attacked by osteoarthritisthreated with Ostenil, Ostenil Plus, Yaral Forte and Durolane. ***J Balk Trib Assoc.*** 2011; 17(3):456-461.	1 (1)				**1**
26	**Публикация № 54** Miteva LD, **IM MANOLOVA**, MG Ivanova, RK Rashkov, RM Stoilov,, MV Gulubova, SA. Stanilova. Functional genetic polymorphisms in interleukin-12B gene in association with systemic lupus erythematosus. ***Rheumatol Int*** 2012; 32:53-59	13(11)		4		**17**
27	**Публикация № 55** Gulubova M.V., J. R. Ananiev, T. I. Vlaykova, Y. Yovchev, V. Tsoneva, **I. M. MANOLOVA** . Role of dendritic cells in progression and clinical outcome of colon cancer. ***Int J Colorectale Disease*** 2012;27(2):159-69	37 (30)	2	2		**41**
28	**Публикация № 57** Tchernev G, Ananiev J, Cardoso JC, Wollina U, Verma SB, Patterson JW,	18 (8)				**18**

	Публикация	Чуждестранно списание (IF)	Моногра-фии	Дисерта-ции	Българско списание	Общо
	Dourmishev LA, Tronnier M, Okamoto H, Mizuno K, Kanazawa N, Gulubova M, **MANOLOVA I**, Salaro C. Sarcoidosis and molecular mimicry - important etiopathogenetic aspects: current state and future directions. ***Wien Klin Wochenschr***. 2012;124(7-8):227-38					
29	**Публикация № 58** **MANOLOVA I**, Gerenova J, Ivanova M. Serum levels OF Transforming Growth Factor-β1 (TGF-β1) in patients with systemic lupus erythematosus and Hashimoto's thyroiditis. ***Eur Cytokine Netw***. 2013 Mar;24(1):69-74.	18 (11)				**18**
30	**Публикация № 59** Gulubova M, **MANOLOVA I**, Ananiev J, Kyurkchiev D, Julianov A, Altunkova I. Relationship of TGF-beta1 and Smad7 expression with decreased dendritic cell infiltration in liver gastrointestinal cancer metastasis. ***APMIS***, 2013;121: 967-975	1 (1)				**1**
31	**Публикация № 60** Stanilova SA, Ivanova MG, Karakolev IA, Stoilov RM, Rashkov RK, **MANOLOVA IM**. Association of +3179G/A insulin-like growth factor-1 receptor polymorphism and insulin-like growth factor-1 serum level with systemic lupus erythematosus**. *Lupus. 2013*** Nov;22(13):1388-93.	10 (5)				**10**
32	**Публикация № 63** **MANOLOVA** I, Ivanova M, Stoilov R, Rashkov R and Stanilova S. Association of single nucleotide polymorphism at position -308 of the tumor necrosis factor-alpha gene with ankylosing spondylitis and rheumatoid arthritis. ***Biotechnol Biotechnol Equip*** 2014; 28: 1108-1114.	9 (7)		2		**11**
33	**Публикация № 66** Ivanova Mariana, **Irena MANOLOVA**, Vladimira Boyadzhieva, Rumen Stoilov, Nedko Dimitrov, Nikolay Stoilov, Berengere Aubry-Rozier, Rasho Rashkov & Didier Hans. Relationship between physical function, disease activity, spinal mobility and bone parameters (trabecular bone score and bone mineral density) in ankylosing spondylitis patients. ***Biotechnology & Biotechnological Equipment*** 2015; 29(5):956-962.	1				**1**
34	**Публикация № 67**	1				**1**

	Публикация	Чуждестранно списание (IF)	Монографии	Дисертации	Българско списание	Общо
	Gerenova, J. **MANOLOVA, I**. and Stanilova,S. Impact of IL-10 and IL-12B single nucleotide polymorphisms on circulating cytokine level in development of Hashimoto's thyroiditis. ***Biotechnology & Biotechnological Equipment*** 2016, 22(48):1-9.					
35	**Публикация № 68** Ivanova M., I. **MANOLOVA**, M. Ganeva, R. Gancheva, R. Stoilov and S. Stanilova. Elevated serum levels of Th17-related cytokines in patients with ankylosing spondylitis. ***Journal of the Balkan Tribological Association*** 2016; 22(3): 2244–2257	1				**1**
36	**Публикация № 69** Ananiev J, **MANOLOVA I**, Aleksandrova E, Guluboba M. Impact of TGF-β1 expression and -509C>T polymorphism in the TGF-β1 gene on the progression and survival of gastric cancer. ***Pol J Pathol*** 2017; 68(3):234-240	1				**1**
37	**Публикация № 70** **MANOLOVA I**, Miteva L, Ivanova M, Kundurzhiev T, Stoilov R, Stanilova S. The Synergistic Effect of TNFA and IL10 Promoter Polymorphisms on Genetic Predisposition to Systemic Lupus Erythematosus. ***Genetic Testing and Molecular Biomarkers***, 2018, DOI:10.1089/gtmb.2017.0169	2 (2)	1			**3**
38	**Публикация № 71** Stanilova S, Stanilov N, Julianov A, **MANOLOVA I**, Miteva L. Transforming growth factor-β1 gene promoter -509C/T polymorphism in association with expression affects colorectal cancer development and depends on gender. ***PLoS One***. 2018 Aug 2;13(8):e0201775. doi: 10.1371/journal.pone.0201775.	1 (1)				**1**
39	**Публикация № 73** Ivanova M, **MANOLOVA I**, Miteva L, Gancheva R, Stoilov R, Stanilova S. Genetic variations in the IL-12B gene in association with IL-23 and IL-12p40 serum levels in ankylosing spondylitis. ***Rheumatol Int.*** 2019, 39(1): 111-119, . doi:10.1007/s00296-018-4204-0	1 (1)				**1**
41	**Публикация № 76** Геренова Ж.Б., **И.М. МАНОЛОВА.** Серумни нива на интерлевкин-18				1	**1**

	Публикация	Чуждестранно списание (IF)	Монографии	Дисертации	Българско списание	Общо
	и при пациенти с тиреоидит на Hashimoto. ***Ендокринология*** 2009, том XIV, бр.2:98-102.					
42	**Публикация № 78** Иванова М., **И. МАНОЛОВА,** Р. Стоилов и К. Пеева. Влиянието на болестната активност и рентгенографската увреда на гръбнака върху физическата функция при анкилозиращ спондилит. ***Ревматология*** XVII, 2009, бр.4:26-32				1	**1**
43	**Публикация № 79** Митева Л., **И. МАНОЛОВА**, М. Иванова, Р. Рашков, Р. Стоилов и С. Станилова. Липса на асоциация между промоторния полиморфизъм -1082A/G в гена за интерлевкин-10 и генетичното предразположение към системен lupus erythematosus. Ревматология XVIII, 2010, бр.3:33-38	1 (1)				**1**
44	**Публикация № 81** Иванова М, Р. Стоилов, **И. МАНОЛОВА**. Остеоартроза – патофизиология и фармакологични средства за лечение. ***Ревматология*** год. XVIII, 4, 2010, 15-21.			1		**1**
45	**Публикация № 82** Иванова М., Р. Стоилов, М. Платиканова и **И. МАНОЛОВА.** Пилотно проучване на серумните нива на TNF-α във връзка с клиничните и лабораторните параметри на болестната активност при българска популация от болни с АС. ***Ревматология*** XIX, 2011, бр.2:25-30.				1	**1**
46	**Публикация № 87** Gerenova Julieta B, **Irena M. MANOLOVA**, Vania I. Tzoneva. Clinical significance of autoantibodies to parietal cells in patients with Hashimoto's thyroiditis. ***Follia Medica***, 2013, 55(2): 26-32.	5 (1)		1		**6**
47	**Публикация № 89** Gerenova J, Avramova A, **MANOLOVA I**, Stanilova S. Association of -1082 A/G promoter polymorphism of IL-10 gene and genetic predisposition to Hashimoto's thyroiditis. ***Endokrinologya***, 2013, 18(2):71-80	1 (1)				**1**
48	**Публикация № 96** Koni Ivanova, **Irena MANOLOVA**, Maria-Magdalena Ignatova, Maya	2				**2**

	Публикация	Чуждестранно списание (IF)	Моногра-фии	Дисерта-ции	Българско списание	Общо
	Gulubova Immunohistochemical Expression of TGF-B1, SMAD4, SMAD7, TGFβRII and CD68-Positive TAM Densities in Papillary Thyroid Cancer. ***Open Access Maced J Med Sci***, 2018; 6(3): 435–441.					
49	**Публикация № 105** **MANOLOVA I.,** L. Miteva, M. Ivanova, Vasilev G., S. Stanilova. Polymorphisms in TNFA and IL10 gene promoters and risk of rheumatoid arthritis in Bulgarian population. ***Trakia J of Science***, 2015; 13(Suppl 2):16-20	1 (1)				**1**
50	**Публикация № 107** **MANOLOVA I**, M. Ivanova and S. Stanilova. Gene polymorphisms of immunoregulatory cytokines Il-10 and TGF-β1 in systemic lupus erythematosus in "genes and autoimmunity – Intracellular signaling and Microbiome contribution". Edited By: Spaska Stanilova ISBN 978-953-51-1028-6, Published: March 13, 2013, Publisher: InTech	3 (2)		1		**4**
	Цитирани публикации – 50	**396 (262 с IF)**	**21**	**22**	**14**	**453**

Интернет връзки към профили на автора в реферира щи бази данни:

Scopus	https://www.scopus.com/authid/detail.uri?authorId=6701814343
Google Scholar	https://scholar.google.bg/citations?user=K_nNOZIAAAAJ&hl=bg

Номерацията в скобите показва поредния номер на статията в списъка с публикации

Цитирана статия (публикация №2):
MANOLOVA I, Dancheva M, Halacheva K. Predominance of IgG1 and IgG3 subclasses of antibodies to neutrophil cytoplasmic antigens in patients with systemic lupus erythematosus: prevalence, antigen specificity and clinical associations. ***Rheumat Int,* 2002,** 21:227-233.

Резултатите са цитирани от:

1. Qin HY, Mahon JL, Atkinson MA, Chaturvedi P, Lee-Chan E, Singh B. Type 1 diabetes alters anti-hsp90 autoantibody isotype. *J Autoimmun* 2003; 20:237-245. **IF_{2003} – 2.353**
2. Hadji-Ghasemi F, Gharagozlou S, Ghods R, et al. Generation and characterization of a mouse monoclonal antibody with specificity similar to staphylococcal protein A (SPA). *Hybridoma Hybridomics* 2003, 22(1): 33-39. **IF_{2003} – 0.447**
3. Caccavo D, Rigon A, Picardi A, et al. Anti-lactoferrin antibodies in systemic lupus erythematosus: isotypes and clinical correlates *Clinical Rheumatology* 2005, 24 (4): 381-387. **IF_{2005} - 1.261**
4. Njoku DB, Mellerson JL, Talor MV, et al. Role of CYP2E1 immunoglobulin G4 subclass antibodies and complement in pathogenesis of idiosyncratic drug-induced hepatitis. *Clinical Vaccine Immunology* 2006, 13 (2): 258-265.
5. Lin, G.-G., Li, J.-M. IgG subclass serum levels in systemic lupus erythematosus patients. *Clinical Rheumatology* 2009, 28 (11) pp. 1315-1318. **IF_{2009} - 1.668**
6. Savitsky DA, Yanai H, Tamura T, Taniguchi T, Honda K. Contribution of IRF5 in B cells to the development of murine SLE-like disease through its transcriptional control of the IgG2a locus. *Proc Natl Acad Sci U S A **2010*** Jun 1;107(22):10154-9. **IF_{2010}- 9.771**
7. Fattal I, Shental N, Mevorach D, et al. An antibody profile of systemic lupus erythematosus detected by antigen microarray. *Immunology **2010*** Jul;130(3):337-43. **IF_{2010} – 3.302**
8. Roy S, Pita PM. IRF-5 - A New Link to Autoimmune Diseases. In book: Autoimmune Disorders – Pathogenetic Aspects" edited by Clio P. Mavragani, InTech, October 2011; ISBN: 978-953-307-643-0
9. Lutz HU. Naturally occurring autoantibodies in mediating clearance of senescent red blood cells. *Adv Exp Med Biol 2012*;750:76-90. **IF_{2012} – 1.093**
10. Lutz HU. Naturally occurring anti-band 3 antibodies in clearance of senescent and oxidatively stressed human red blood cells. *Transfus Med Hemother.* 2012; 39(5):321-7. **IF_{2012} – 1.164**
11. Hjelholt A, Carlsen T, Deleuran B, Jurik AG, Schiøttz-Christensen B, Christiansen G, Birkelund S. Increased Levels of IgG Antibodies against Human HSP60 in Patients with Spondyloarthritis. *PLoS One **2013***;8(2):e56210. **IF_{2013} – 3.73**
12. Lutz HU, Bogdanova A. Mechanisms tagging senescent red blood cells for clearance in healthy humans. *Front Physiol* 2013 Dec 25;4:387.
13. Pepper RJ, SV Parikh, L Lightstone, BH Rovin - Lupus Nephritis and Novel Therapies, Pathogenesis. In book: "Encyclopedia of Medical Immunology – Autoimmune Diseases." Mackay, I., Rose, N.R., Diamond, B., Davidson, A. (Eds) Springer-Verlag New York 2014; ISBN 978-0-387-84827-3

Цитирана статия (публикация №3):

МАНОЛОВА И., К. Халачева, М Данчева. Проучване на антитела срещу цитоплазмени антигени на неутрофилите (АНЦА) при болни със системен лупус еритематодес (СЛЕ). ***Българска Медицина*** 2002, том X,бр.1:10-12

Резултатите са цитирани от:

14. Николова М, Цекова Д, Тодоров Т, Влахов Й, Киперова Б, Джераси Р. Честота и клинично значение на антинеутрофилните цитоплазмени антитела (ANCA) при пациенти с идиопатични гломерулонефрити и системен lupus erythematosus със и без данни за бъбречно засягане. *Ревматология*, 2003, том XI, бр.1-2:33-36

15. Nikolova, M. Лупусен нефрит - етиология, патогенеза, клинико-лабораторни характеристики; Lupus nephritis - etiology, pathogenesis and clinico-laboratory characteristics / M. Nikolova. // *Nefrol., khemodial. i transpl*., 9, 2003, N 1, ISSN 1310-7828 , с. 15-22, Sum. Bulg., Engl. 23 ref.

16. Nikolova, M. Диагностична стойност на някои лабораторни показатели при пациенти със системен Lupus erythematosus и лупусен нефрит (обзор); Diagnostic value of some laboratory parameters in patients with systemic Lupus erythematosus and Lupus nephritis (review) / M. Nikolova. // *Med. pregled*, 39, 2003, N 2, ISSN 0204-7241 , с. 24-34, 3 tabl. Sum. Bulg., Engl. 45 ref.

Цитирана статия (публикация №7):

МАНОЛОВА И., И. Алтънкова, М. Огнянов. Клинично занчение на антителата срещу неутрофилни цитоплазмени съставки. ***Съвременна медицина***, год.XLII, кн. 7, 4-7, 1991

Резултатите са цитирани от:

17. Dinev, D. Васкулити; Vasculitis / D. Dinev. // *Revmatologiia*, 1, 1993, N 1, ISSN 1310-0505 , с. 9-14, 2 tabl. 10 ref.

Цитирана статия (публикация №10):

Halacheva K, **MANOLOVA I,** Petkov D, Andreev A. Study of antineutrophil cytoplasmic antibodies in Thromboangiitis Obliterans (buerger's disease). ***Scand. J. Immunol***, 1998, 48:544-550.

Резултатите са цитирани от:

18. Vassilopoulos D**,** Hoffman GS. Clinical utility of testing for antineutrophil cytoplasmic antibodies. *Clin Diagn Lab Immunol* 1999; 6:645-651. **IF_{1999}- 1.483**

19. Reny J-L**,** Emmerich J. Physiopathologie et traitement de la maladie de Buerger: quels niveaux de preuve? *Sang Thrombose Vaissea* 1999; 11:596-602

20. Brodmann M, Renner W, Stark G, Winkler M, Pabst E, Hofmann C, Pilger E. Prothrombotic risk factors inpatients with thrombangitis obliterans. *Thromb Res* 2000; 99:483-486. **IF_{2000}- 1.323**

21. Ehrenfeld, M., Papa, M., Adar, R. Autoimmune mechanisms in Buerger's disease. *Critical Ischaemia* 2001, 11 (1), pp. 7-13

22. Hoefflin SM, Rubin A. Smoking and cool face lifts; is there a Buerger's type disease of the face? *Plast Reconstr Surg* 2001; 107:1316-1318. **IF_{2001}- 1.436**

23. Hoefflin, S.M., Rubin, A. A simple aid to skin closure [12]. *Plastic and Reconstructive Surgery* 2001; 107 (5), pp. 1315-1316 **IF_{2001}- 1.436**

24. Espinosa, G., Llambrich, A., Ingelmo, M. Tromboangeítis obliterante. *Med. Integral 2001; 37(4): 154-159.*

25. Puszczewicz, M. Antineutrophil cytoplasmic antibodies (ANCA) | [Przeciwciała przeciw cytoplazmie granulocytów obojętnochłonnych (ANCA)]. *Reumatologia* 43 2005; (6), pp. 341-348

26. Kroger K. Buerger's disease: What has the last decade taught us? *Eur J Internal Med* 2006; 17 (4): 227-234

27. Malecki, R., Zdrojowy, K., Adamiec, R. Thromboangiitis obliterans in the 21st century-A new face of disease *Atherosclerosis, 2009,* 206 (2) pp. 328-334. **IF_{2009} – 4.522**

28. Espinoza, L.R. Buerger's disease: Thromboangiitis obliterance 100 years after the initial description. *American Journal of the Medical Science 2009*;337(4):285-286. **IF_{2009} -1.195**

29. Baumann G, Stangl V, Klein-Weigel P, Stangl K, Laule M, Enke-Melzer K. Successful treatment of thromboangiitis obliterans (Buerger's disease) with immunoadsorption: results of a pilot study. *Clin Res Cardiol* 2011, 100(8):683-90.

30. Klein-Weigel, P.F., Köning, C., Härtwig, A., Krüger, K., Gutsche-Petrak, B., Dreusicke, S., Thieme, U., Enke-Melzer, K., Urbach, B., Kron, J. Immunoadsorption in thrombangiitis obliterans - A promising therapeutic optionresults of a consecutive patient cohort treated in clinical routine care. *Zentralblatt fur Chirurgie - Zeitschrift fur Allgemeine, Viszeral- und Gefasschirurgie***,** 2012, 137 (5), pp. 460-465.

31. Ketha, S.S., Cooper, L.T. The role of autoimmunity in thromboangiitis obliterans (Buerger's disease. (2013*) Annals of the New York Academy of Sciences*, 1285 (1), pp. 15-25. **$IF2_{013}$ – 4.375**

32. Guo Y, Y Dai, J Lai, Y Fan. Study about correlation of anti-neutrophil cytoplasmic antibodies and anticardiolipin antibodies with thromboangiitis obliterans. *Vascular*, 2013: 21 (6) pp. 363 - 368 . **IF_{2013} – 0.861**

33. Iwai T, M Umeda, Y Inoue. Pathogenic Mechanism of the Artery and the Vein in Buerger Disease: Our Hypothesis. *Angiol* 2014;2:3 http://dx.doi.org/10.4172/2329-9495.1000131 **IF_{2013} – 1,647**

34. Klein-Weigel PF, Bimmler M, Hempel P, Schöpp S, Dreusicke S, Valerius J,Bohlen A, Boehnlein JM, Bestler D, Funk S, Elitok S. G-protein coupled receptor auto-antibodies in thromboangiitis obliterans (Buerger's disease) and their removal by immunoadsorption. *Vasa.* 2014; 43(5):347-52. **IF_{2013} – 1,01**

35. Klein-Weigel PF, Richter JG. Thromboangiitis obliterans (Buerger's disease). *Vasa.* 2014; 43(5):337-46. **IF_{2013} – 1,01**

36. Klein-Weigel P, Volz TS, Zange L, Richter J. Buerger's disease: providing integrated care. *Journal of Multidisciplinary Healthcare* 2016; 9:511-518. doi:10.2147/JMDH.S109985.

37. Luqmani R. Polyarteritis nodosa and related disorders IN: Kelley and Firestein's Textbook of Rheumatology, 2-volume Set, 10th Edition. Edd:Tom S. Elsevier, 2017

Цитирана статия (публикация №11):

MANOLOVA I, Dancheva M, Halacheva K. Anti-neutrophil cytoplasmic antibodies in patients with systemic lupus erythematosus: prevalence, antigen specificity and clinical associations. ***Rheumat Int,*** 2001,20:197-200

Резултатите са цитирани от:

38. Hachulla, É., De Bandt, M., Dubucquoi, S., Vittecoq, O., Le Loët, X., Meyer, O. Value of measurement of antinuclear antibodies, antiphospholipid antibodies and antineutrophil cytoplasmic antibodies in the diagnostic classification of early onset

chronic inflammatory arthritis without clinicals signs. *Revue Du Rhumatisme (Edition Francaise)* 2002; 69 (2), pp. 139-146

39. Sen D, Isenberg DA. Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus. *Lupus* 2003, 12(9): 651-658. **IF_{2003} -1.808**

40. Guma M, Salinas I, Reverter JL, et al. Frequency of antineutrophil cytoplasmic antibodies in Graves' disease patients treated with methimazole. *J Clin Endocrinol Methabolism* 2003, 88(5): 2141-2146. **IF_{2003} -5.873**

41. Fessler, B.J., Rendt, K.E., Hoffman, G.S. Systemic lupus erythematosus and the cardiovascular system: Vasculitis (Book Chapter) IN : Lahita, R.G.(eds) Systemic Lupus Erythematosus, Elsevier Inc, Newark, NJ, 2004 ISBN: 978-012374994-9: pp, pp. 943-959

42. Reveille J. Predictive value of autoantibodies for activity of systemic lupus erythematosus. *Lupus* 2004, 13(5): 290-297. **IF_{2004}-1.942**

43. Chen M, Zhao MH, Zhang Y et al. Antineutrophil cytoplasmic antibodies and their target antigens in systemic lupus erythematosus. *Lupus* 2004, 13(8): 584-589. **IF_{2004}-1.942**

44. Sinclair D, Saas M, Stevens JM. The effect of a symptom related"gating policy" on ANCA requests in routine clinical practice. *J Clin Pathol* 2004, 57: 131-134 **IF_{2004} – 2.619**

45. Pradhan, V.D., Badakere, S.S., Bichile, L.S., Almeida, A.F. Anti-neutrophil Cytoplasmic Antibodies (ANCA) in systemic lupus erythematosus: Prevalence, clinical associations and correlation with other autoantibodies. *Journal Association Physicians India* 2004, 52 (JUL), pp. 533-537

46. Masani NN, Imbriano LJ, D'Agati VD, et al. SLE and rapidly progressive glomerulonephritis. *Amer J Kidney Dis* 2005; 45 (5): 950-955. **IF_{2005} – 4.412**

47. Caccavo D, Rigon A, Picardi A, et al. Anti-lactoferrin antibodies in systemic lupus erythematosus: isotypes and clinical correlates. *Clin Rheumatol* 2005, 24 (4): 381-387. **IF_{2005} – 1.261**

48. Chen M, Wang YY, Zhao MH, et al. Autoantibodies against glomerular mesangial cells and their target antigens in lupus nephritis. *Renal Failure* 2005, 27 (5): 507-513. **IF_{2005} – 0.54**

49. Chen M, Zhao MH, Zhang YK, et al. Antineutrophil cytoplasmic autoantibodies in patients with systemic lupus erythematosus recognize a novel 69 kDa target antigen of neutrophil granules. *Nephrology* 2005, 10 (5): 491-495. **IF_{2005} – 1.023**

50. Puszczewicz, M. Antineutrophil cytoplasmic antibodies (ANCA) [Przeciwciała przeciw cytoplazmie granulocytów obojętnochłonnych (ANCA)]. *Reumatologia* 2005; 43 (6), pp. 341-348

51. Chang A, Aneziokoro O, Meehan SM, et al. Membranous and crescentic glomerulonephritis in a patient with anti-nuclear and anti-neutrophil cytoplasmic antibodies. *Kidney Intern* 2007, 71 (4): 360-365. **IF_{2007}- 4.922**

52. Hirai Y, Iyoda M, Shibata T, Ashikaga E, Hosaka N, Suzuki H, Nagai H, Mukai M, Honda H, Kuroki A, Kitazawa K, Akizawa T. Lupus nephritis associated with positive MPO-ANCA in a patient with underlying autoimmune hemolytic anemia. *Clin Exp Nephrol.* 2008 Oct;12(5):393-7

53. Wada Y, Kuroda T, Murasawa A, Nakano M, Narita I. Anti-neutrophil cytoplasmic autoantibodies against bactericidal/permeability-increasing protein in patients with rheumatoid arthritis and their correlation with bronchial involvement. *Mod Rheumatol* 2010 Jun;20(3):252-6. **IF_{2010} - 1.8**

54. Isono M, Araki H, Haitani T, et al. Diffuse alveolar hemorrhage in lupus nephritis complicated by microscopic polyangiitis. *Clin Exp Nephrol* 2011 Apr;15(2):294-8. **IF_{2011} - 1.369**

55. Dwivedi N. Autoimmune consequences of histone deamination during neutrophilm activation. Dissertation. University of Tennessee, 2011

56. Fessler, B.J**.,** Hoffman, G.S. Chapter: Vasculitis IN: Lahita, R.G.(eds) Systemic Lupus Erythematosus, Elsevier Inc, Newark, NJ, 2011 ISBN: 978-012374994-9: pp. 833-845.

57. Knight JS, Jason S.; Kaplan, Mariana J. Lupus neutrophils: 'NET' gain in understanding lupus pathogenesis. *Current Opinion in Rheumatology* 2012, 24(5): 441–450. **IF_{2012} - 4.309**

58. Dwivedi N, J Upadhyay, I Neeli, et al. Felty's syndrome autoantibodies bind to deiminated histones and neutrophil extracellular chromatin traps. *Arthritis & Rheumatism* 2012 Volume 64 (4):982–992. **IF_{2012} - 7.866**

59. Sangaletti S, Tripodo C, Chiodoni C, et al. Neutrophil extracellular traps mediate transfer of cytoplasmic neutrophil antigens to myeloid dendritic cells toward ANCA induction and associated autoimmunity. *Blood* 2012 Oct 11;120(15):3007-18. **IF_{2012} - 9.898**

60. Darrah E, Andrade F. NETs: the missing link between cell death and systemic autoimmune diseases? *Front Immunol* 2012; 3:428.

61. Knight JS, Carmona-Rivera C, Kaplan MJ. Proteins derived from neutrophil extracellular traps may serve as self-antigens and mediate organ damage in autoimmune diseases. *Front Immunol* 2012; 3:380.

62. Hervier B, M Hamidou, J Haroche, C Durant. Systemic lupus erythematosus associated with ANCA-associated vasculitis: an overlapping syndrome? *Rheumatol Int.* 2012 Oct;32(10):3285-90 **IF_{2012} - 1.855**

63. Darrah, E., Andrade, F. Nets: The missing link between cell death and systemic autoimmune diseases? *Front Immunol* 2013, 3:428

64. Carmona-Rivera C, MJ Kaplan. Detection of SLE Antigens in Neutrophil Extracellular Traps (NETs). IN: Eggleton P and Ward FJ (eds)" Systemic Lupus Erythematosus: Methods and Protocols" Springer Science+Business Media New York, 2014, ISBN: 978-1-4939-0325-2; pp 151-161

65. Dwivedi N, Radic M. Citrullination of autoantigens implicates NETosis in the induction of autoimmunity. *Ann Rheum Dis* 2014 Mar 1;73(3):483-91. **IF_{2013} - 9.111**

66. Dwivedi N, Neeli I, Schall N, Wan H, Desiderio DM, Csernok E, Thompson PR, Dali H, Briand JP, Muller S, Radic M. Deimination of linker histones links neutrophil extracellular trap release with autoantibodies in systemic autoimmunity. *FASEB J.* 2014; 28:(7) pp. 2840 – 2851. **IF_{2013} - 5.704**

67. Carmona-Rivera C, Kaplan MJ. Detection of SLE antigens in neutrophil extracellular traps (NETs). *Methods Mol Biol*. 2014;1134:151-61

68. Wang Y, Huang X, Cai J, Xie L, Wang W, Tang S, Yin S, Gao X, Zhang J, Zhao J, Huang Y, Li Y, Zhang Y, Zhang J. Clinicopathologic Characteristics and Outcomes of Lupus Nephritis With Antineutrophil Cytoplasmic Antibody: A Retrospective Study. *Medicine (Baltimore)* 2016; 95(4): e2580.

69. Mahajan A, Herrmann M, Munoz LE. Clearance deficiency and cell death pathways: A model for the pathogenesis of SLE. *Front Immunol* 2016 | http://dx.doi.org/10.3389/fimmu.2016.00035 **SJR - 2.963**

70. Zhan X, Q Liu, L Fan, L Hong, Q Zhou, W Chen.. Yu X. Clinicopathological characteristics and outcomes of patients with ANCA-positive lupus nephritis: a large

cohort study from a single Chinese center. *Int J Clin Exp Pathol* 2016; 9(2):1819-1828 www.ijcep.com /ISSN:1936-2625/IJCEP0018240 **IF_{2014} – 1.891**

71. Zhang, W., Yuan, M., Hong, L., Zhou, Q., Yang, S., Yang, Q., Chen, W., Yu, X. Clinical outcomes of lupus nephritis patients with different proportions of crescents. *Lupus.* 2016;25(14):1532-1541. **IF_{2014} – 2.197**

72. Su F, Xiao W, Yang P, Chen Q, Sun X, Li T. Anti-neutrophil cytoplasmic antibodies in new-onset systemic lupus erythematosus. *An Bras Dermatol.* 2017;92(4):466-469. **IF_{2016} – 0.978**

73. Li C, Zhou ML, Liang DD, Wang JJ, Yang J, Zeng CH, Liu ZH, Zhang HT. Treatment and clinicopathological characteristics of lupus nephritis with anti-neutrophil cytoplasmic antibody positivity: a case-control study. *BMJ Open*. 2017; 7(7):e015668. **IF_{2016} – 2.369**

74. Olson SW, Lee JJ, Poirier M, Little DJ, Prince LK et al. Anti-Myeloperoxidase Antibodies Associate with Future Proliferative Lupus Nephritis. *Autoimmune Dis* 2017 (2017) Article ID 1872846 **SJR-0.852**

75. Curtiss P, Liebman T, Khorolsky C, Brinster N, Beasley J, Lo Sicco K. Systemic lupus erythematosus and antineutrophil cytoplasmic antibody–associated vasculitis: An emerging overlap syndrome with cutaneous manifestations. *JAAD Case Reports*. 2018; 4: 493-496. 10.1016/j.jdcr.2018.01.021. **SJR-0.78**

76. Skopelja-Gardner S, Jones JD, Rigby WFC. "NETtling" the host: Breaking of tolerance in chronic inflammation and chronic infection. J *Autoimmun*. 2018;88:1-10. doi: 10.1016/j.jaut.2017.10.008. **IF_{2016} – 7.641**

77. Van Dam LS, Rabelink TJ, van Kooten C, Teng YKO. Clinical implications of excessive neutrophil extracellular trap formation in renal autoimmune diseases. *Kidney Int Rep*, November 2018, DOI: 10.1016/j.ekir.2018.11.005

Цитирана статия (публикация №12):

Halacheva K, Gulubova M, **MANOLOVA I.,** and Petkov D. Expression of ICAM-1, VCAM-1, E-selectin and TNF-α on the endothelium of femoral and iliac arteries in thromboangiitis obliterans. ***Acta histochem,*** 2002,104:177-184

Резултатите са цитирани от:

78. Lee T, Seo JW, Sumpio BE, et al. Immunobiologic analysis of arterial tissue in Buerger's disease. *Eur J Vasc Endovasc* 2003, 25: 451-457 **IF_{2003} - 1.774**

79. Krug M, Wunsche A, Blun A. Addiction to tabacco and the consequences for the skin. *Hautarzt* 2004, 55(3): 310-315. **IF_{2004} – 0.461**

80. Manfredini R, Boari B, Gallerani M, La Cecilia R, De Toma D, Galeotti R, Ragazzi R. Thromboangiitis obliterans (Buerger's disease) in a female mild smoker treated with spinal cord stimulation. *Amer J Medical Sci* 2004, 327(6): 365-368. **IF_{2004} – 1.795**

81. Hoeft, D., Kroger, K., Grabbe, S., Dissemond, J. Thromboangiitis obliterans: An overview. [Thrombangiitis obliterans: Eine übersicht] *JDDG - Journal of The German Society of Dermatology* 2004, 2 (10):827-832.

82. Maksimowicz-McKinnon, K., Bhatt, D.L., Calabrese, L.H. Recent advances in vascular inflammation: C-reactive protein and other inflammatory biomarkers. *Current Opinion In Rheumatology* 2004, 16 (1):18-24. **IF_{2004} - 2.984**

83. Slavov ES, Stanilova SA, Petkov DP, et al. Cytokine production in thromboangiitis obliterans patients: New evidence for an immune-mediated inflammatory disorder. *Clin Exp Rheumat* 2005, 23 (2): 219-226. **IF_{2005} – 2.366**

84. Kroger K. Buerger's disease: What has the last decade taught us? *Eur J Intern Med* 2006, 17 (4): 227-234.
85. Olin, J.W. Thromboangiitis obliterans (Buerger's Disease)(Book Chapter). IN : Creager MA (Eds) "Vascular Medicine", Elsevier Inc 2006, ISBN: 978-07216028404, pp. 641-656
86. Chen, Y.-W., Iwai, T., Umeda, M., Nagasawa, T., Huang, Y., Takeuchi, Y., Ishikawa, I. Elevated IgG titers to periodontal pathogens related to Buerger disease. *International Journal of Cardiology* 2007, 122 (1), pp. 79-81 **IF_{2008} - 2.324**
87. Tran, E.D., Schmid-Schönbein, G.W. An in-vivo analysis of capillary stasis and endothelial apoptosis in a model of hypertension. *Microcirculation* 2007, 14 (8), pp. 793-804. **IF_{2007} - 2.955**
88. Maruotti, N**.,** Cantatore, F.P., Nico, B., Vacca, A., Ribatti, D. Angiogenesis in vasculitides. *Clinical And Experimental Rheumatology*, 2008; 26 (3) pp. 476-483 . **IF_{2008} – 2.364**
89. Xu, Y., Li, S. Blockade of ICAM-1: A novel way of vasculitis treatment. *Biochemical And Biophysical Research Communications*, 2009; 381 (4) pp. 459-461. **IF_{2009} – 2.548**
90. Malecki, R., Zdrojowy, K., Adamiec, R. Thromboangiitis obliterans in the 21st century- A new face of disease**.** *Atherosclerosis* 2009, 206 (2) pp. 328-334. **IF_{2009} – 4.522**
91. Joviliano EE, Dellalibera-Joviliano R, Dalio M, Evora PR, Piccinato CE. Etiopathogenesis, clinical diagnosis and treatment of thromboangiitis obliterans - current practices. *Int J Angiol* 2009; 18(3):119-25. **IF_{2009} – 1.155**
92. Xu Y, Zhang R, Chen J, Zhang Q, Wang J, Hu J, Guan X, Jin L, Fu H, Gui B, Guo Y, Li S. Urocortin promotes the development of vasculitis in a rat model of thromboangiitis obliterans via corticotrophin-releasing factor type 1 receptors. *Br J Pharmacol* 2009; 157(8):1368-79. **IF_{2009} – 5.204**
93. Zhang R, Xu Y, Fu H, Wang J, Jin L, Li S. Urocortin induced expression of COX-2 and ICAM-1 via corticotrophin-releasing factor type 2 receptor in rat aortic endothelial cells. *Br J Pharmacol* 2009; 158(3):819-29. **IF_{2009} – 5.204**
94. Guzel E, Topal E, Yildirim A, Atilla P, Akkus M, Dagdeviren A. Targeting novel antigens in the arterial wall in thromboangiitis obliterans. *Folia Histochem Cytobiol* 2010; 48(1):134-41. **IF_{2010} – 0.902**
95. Park, U.-J., Kim, D.-I. Thromoboagiitis obliterans (TAO). *International Journal of Stem Cells,* 2010, 3 (1): 1-7.
96. Porquet N. Etude de l'implication de la E-selectine et de son récepteur, le death receptor 3, dans le processus métastatique. Mémoire présenté à la Faculté des études supérieures de l'Université Laval dans le cadre du programme de Maîtrise en Biologie Cellulaire et Moléculaire pour l'obtention du grade de Maître es Science (M. Sc.) 2010. FACULTÉ DE MEDECINE UNIVERSITÉ LAVAL QUÉBEC
97. Fazeli B, Rezaee SA. A review on thromboangiitis obliterans pathophysiology: thrombosis and angiitis, which is to blame? *Vascular* 2011 May-Jun;19(3):141-53. **IF_{2011} – 0.89**

98. Porquet N, Huot J**.** Signal Transduction in Tumor-Endothelial Cell Communication IN: Liver Metastasis: Biology and Clinical Management, Pnina Brodt (Eds) Springer Science 2011, ISBN: 978-94-007-0291-2, pp. 187-212.

99. Dellalibera-Joviliano R, EE Joviliano. Activation of cytokines corroborate with development of inflammation and autoimmunity in thromboangiitis obliterans patients. *Clinical & Experimental Immunology* 2012; 170(1)**:**28–35. **IF_{2012}-3.36**

100. Kong X, Yuan H, Wu X, Zhang J, Zhou H, Wang M, Liu Y, Jin X. High-mobility-group box protein 1 A box reduces development of sodium laurate-induced thromboangiitis obliterans in rats. *J Vasc Surg* 2013;57(1):194-204.

101. Vijayakumar, A., Tiwari, R., Kumar Prabhuswamy, V. Thromboangiitis obliterans (Buerger's Disease) - Current practices. *International Journal of Inflammation* 2013 , art. no. 156905

102. Maruotti N, Annese T, Cantatore FP, Ribatti D. Macrophages and angiogenesis in rheumatic diseases. *Vasc Cell*. 2013;5(1):11.

103. Ketha, S.S., Cooper, L.T. The role of autoimmunity in thromboangiitis obliterans (Buerger's disease. *Annals of the New York Academy of Sciences* 2013, 1285 (1):15-25. **IF_{2013} – 4.38**

104. Fazeli B, Rafatpanah H, Ravari H, Farid Hosseini R, Tavakol Afshari J, Hamidi Alamdari D, Valizadeh N, Moheghi N, Rezaee SA. Sera of patients with thromboangiitis obliterans activated cultured human umbilical vein endothelial cells (HUVECs) and changed their adhesive properties. *Int J Rheum* Dis 2014;17(1):106-12. **IF_{2013} – 1.65**

105. Maruotti, N., Cantatore, F.P., Ribatti, D. Putative effects of potentially anti-angiogenic drugs in rheumatic diseases. *Eur J Clinical Pharmacology* 2014; 70(2):135 – 140. **IF_{2013} – 2.741**

106. Klein-Weigel PF, Bimmler M, Hempel P, Schöpp S, Dreusicke S, Valerius J, Bohlen A, Boehnlein JM, Bestler D, Funk S, Elitok S. G-protein coupled receptor auto-antibodies in thromboangiitis obliterans (Buerger's disease) and their removal by immunoadsorption. *Vasa* 2014 ; 43(5):347-52. **IF_{2013} – 1.21**

107. Klein-Weigel PF, Richter JG. Thromboangiitis obliterans (Buerger`s disease). *Vasa* 2014 ; 43(5):337-46. **IF_{2013} – 1.21**

108. Kobayashi, M., Sugimoto, M., Komori, K. Endarteritis obliterans in the pathogenesis of buerger's disease from the pathological and immunohistochemical points of view. *Circ J.* 2014; 78(12):2819-26. **IF_{2013} – 3.578**

109. Saito, K., Sato, T., Sato, A., Shibatomi, K., Tashiro, M., Hatano, Y. A case of upper limb Buerger's disease with severe periodontitis. *Nishinihon Journal of Dermatology* 2015; **77** (5) pp. 465 – 468

110. CY Ng, Y Kamisah, K Jaarin Immunohistochemistry on Rodent Circulatory System: Its Possible Use in Investigating Hypertension In: Technical Aspects of Toxicological Immunihistochemistry, pp 147-177, 24 December 2016 – Springer

111. Igari K, Inoue Y, Iwai T. The Epidemiologic and Clinical Findings of Patients with Buerger Disease. *Ann Vasc Surg* 2016; 30: 263-9. **IF_{2015} – 1.17**

112. Sugimoto M, K Komori. Buerger's Disease (Thromboangiitis Obliterans) IN: Systemic Vasculitides: Current Status and Perspective, Eds: Dammacco F, Ribatti D, Vacca A, 2016 – Springer, pp361-376.

113. Klein-Weigel P, Volz TS, Zange L, Richter J. Buerger's disease: providing integrated care. *Journal of Multidisciplinary Healthcare.* 2016; 9:511-518. doi:10.2147/JMDH.S109985.

114. Foudi N, Badi A, Amrane M, Hodroj W. Asthma causes inflammation of human pulmonary arteries and decreases vasodilatation induced by prostaglandin I(2) analogs. *J Asthma.* 2017; 54(10):1012-1018. doi: 10.1080/02770903.

115. Wu, S., Sun, X., Wu, W., Shi, D., Jiang, T."Effect of revascularization on IL-6 and TNF-α in patients with thromboangiitis obliterans". *Experimental and Therapeutic Medicine* 2018; 15 (4): 3947-3951. https://doi.org/10.3892/etm.2018.5877

116. Ziru Z, Mingyi M, Longru S. Inhibitory Effect of Tanshinones on TNF-α-induced Inflammation in Human Aortic Endothelial Cells. *Medicinal Plant* [serial online]. June 2018;9(3):25-30.

117. Song F, Ji B, Chen T. Cilostazol on the expression of ICAM-1, VCAM-1 and inflammatory factors in plasma in patients with thromboangiitis obliterans. *Exp Ther Med.* 2018 Sep;16(3):2349-2354. doi: 10.3892/etm.2018.6436. **IF_{2017} – 1.41**

118. Tavakol J, Shapouri-Moghaddam A, Saeed Modaghegh MH, Rahimi HR, Ehteshamfar SM, Tavakol Afshari J. Molecular mechanisms regulating immune responses in thromboangiitis obliterans: a comprehensive review. *Iran J Basic Med Sci* 2019; 22(3):215. DOI: 10.22038/ijbms.2019.31119.7513 **IF_{2017} – 1.514**

Цитирана статия (публикация №13):
MANOLOVA I, Dancheva M. Antineutrophil cytoplasmic antibodies (ANCA) in patients with systemic sclerosis. ***J Rheumatol***, 2003, 30: 2078-79.

Резултатите са цитирани от:

119. Bocci, E.B., Giordano, A., Luccioli, F., Alunno, A., Gerli, R. Crescentic glomerulonephritis and circulating antineutrophil cytoplasmic antibodies in scleroderma: a case report and review of the literature. *Clinical and Experimental Rheumatology* 2009; 27(2):385-386. **IF_{2009} - 3,01**

120. Patel FB, Couch KS, McNish S, Miller JD, Siegel R, Easley S, Shanmugam VK. A 66-Year-Old Woman With Hemoptysis. *Arthritis Care Res (Hoboken*). 2017; 69(3):439-448. doi: 10.1002/acr.22820.

Цитирана статия (публикация №14):
MANOLOVA I., M. Dantcheva. Antineutrophil cytoplasmic antibodies (ANCA) in Bulgarian patients with rheumatoiod artritis: characterization and clinical associations. ***Rheumat Int*** 2005, 26(2):107-14.

Резултатите са цитирани от:

121. Talor, M.V., Stone, J.H., Stebbing, J., Barin, J., Rose, N.R., Burek, C.L. Antibodies to selected minor target antigens in patients with anti-neutrophil cytoplasmic antibodies (ANCA). *Clinical Experimental Immunology* 2007, 150(1):42-48. **IF_{2007} - 2.599**

122. Eiras, A., Vizcaíno, L., Eiras Martínez, P. Antineutrophil cytoplasmic antibodies in nonvasculitis diseases: Clinical correlates and target antigens. *Revista Clinica Espanola* 2007, 207(7):341-343.

123. Lavergne, S.N., Drescher, N.J., Trepanier, L.A. Anti-myeloperoxidase and anti-cathepsin G antibodies in sulphonamide hypersensitivity. *Clinical Experimental Allergy* 2008, 38(1):199-207. **IF_{2008} - 3.556**

124. Eiras, P. Anti-neutrophil cytoplasmic antibodies: Other target antigens. *Seminarios de la Fundacion Espanola de Reumatologia* 2008, 9(3):156-165.

125. Knight A, Ekbom A, Brandt L, Askling J. What is the significance in routine care of c-ANCA/PR3-ANCA in the absence of systemic vasculitis? A case series. Clin exp rheumatol. 2008;26(3 Suppl 49):S53-6. **IF_{2008} - 2.364**

126. Kaliyadan F. Erythema Elevatum Diutinum presenting with vesicular lesions in the setting of rheumatoid arthritis and p-ANCA positivity. *Egyptian Dermatology Online Journal* 2009; 5(1): 7.

127. Wada Y, Kuroda T, Murasawa A, Nakano M, Narita I. Anti-neutrophil cytoplasmic autoantibodies against bactericidal/permeability-increasing protein in patients with rheumatoid arthritis and their correlation with bronchial involvement. *Mod Rheumatol.* 2010; 20(3):252-6. **IF_{2010} - 1.8**

128. Kida I, Kobayashi S, Takeuchi K, Tsuda H, Hashimoto H, Takasaki Y. Antineutrophil cytoplasmic antibodies against myeloperoxidase, proteinase 3, elastase, cathepsin G and lactoferrin in Japanese patients with rheumatoid arthritis. *Mod Rheumatol* 2011 Feb;21(1):43-50. **IF_{2011} - 1.577**

129. Al-Rubaye MR, Abdul-Qader SJ, Abdul–majeed NG, Kamil KM. The Role of Anti- Cathapsin G among Patients with Rheumatiod Arthritis. *J Fac Med Baghdad* 2012; 54(1): 68-72

130. Debard A, Thibaudin L, Thibaudin D, Monard E, Alamartine E, Cathébras P. *Journal of Autoimmune Diseases and Rheumatology*, 2013, 1(2): 36-45

131. NG Abdul–Majeed, MR Al-Rubaye, NA Ameen. Frequency of Anti Lactoferrin Antibodies in Patients With Systemic Lupus Erythematosus and Rheumatoid Arthriti. Iraqi *Academic Scientific J* 2014: 13 (4):571-577.

132. Jameel SK. Assessment of Urinary Tract Infection and Anti Lactoferrin Antibodies Levels in Iraqi Patients with Rheumatoid Arthritis. *Jornal of Biotechnology Research Center* 2016; 10(2):20-24.

133. Attenberger CK. ANCA-Diagnostik in der klinischen Routine. *Dissertation* zur Erlangung des Doktorgrades der Medizinder Fakultät für Medizin der Universität Regensburg - 2019

Цитирана статия (публикация №15):

Gulubova M, **MANOLOVA I**, Vlaykova T, Prodanova M, Jovchev J. Adhesion molecules in chronic ulcerative colitis. ***Intern J Colorectal Dis*** 2007 Jun;22(6):581-9.

Резултатите са цитирани от:

134. Mirbagheri SA, Nezami BG, Assa S, Hajimahmoodi M. Rectal administration of d-alpha tocopherol for active ulcerative colitis: a preliminary report. *World J Gastroenterol* 2008; 14(39):5990-5. **IF_{2008} – 2.092**

135. Shi, H.-X**.,** Ren, J.-L., Dong, W.-G. Advances in studies on relation between inflammatory bowel disease and immunity. *World Chinese Journal of Digestology* 2008; 16(4):399-405.

136. Roifman I, Sun YC, Fedwick JP, Panaccione R, Buret AG, Liu H, Rostom A, Anderson TJ, Beck PL. Evidence of endothelial dysfunction in patients with inflammatory bowel disease. *Clin Gastroenterol Hepatol* 2009; 7(2):175-82 **IF_{2009} – 5.642**

137. Yoshizaki A, Nakayama T, Naito S, Sekine I. Expression patterns of angiopoietin-1, -2, and tie-2 receptor in ulcerative colitis support involvement of the angiopoietin/tie pathway in the progression of ulcerative colitis**.** *Dig Dis Sci* 2009; 54(10):2094-9. **IF_{2009} - 1.838**

138. Chu, Z.-X., Qin, H.-L. Progress of gut associated lymphocyte homing in inflammatory bowel disease. *World Chinese Journal of Digestology* 2009; 17(7)687-693.

139. Kum WW, Lo BC, Deng W, Ziltener HJ, Finlay BB. Impaired innate immune response and enhanced pathology during Citrobacter rodentium infection in mice lacking functional P-selectin. *Cell Microbiol* 2010; 12(9):1250-71. **IF_{2010} – 5.625**

140. Guri AJ, Hontecillas R, Bassaganya-Riera J. Abscisic acid ameliorates experimental IBD by downregulating cellular adhesion molecule expression and suppressing immune cell infiltration**.** *Clin Nutr* 2010; 29(6):824-31. **IF_{2010} – 3.41**

141. Dagia NM, Agarwal G, Kamath DV, et al. A preferential p110alpha/gamma PI3K inhibitor attenuates experimental inflammation by suppressing the production of proinflammatory mediators in a NF-kappaB-dependent manner. *Am J Physiol Cell Physio.* 2010; 298(4):C929-41. **IF_{2010} – 3.817**

142. M'Koma AE, Seeley EH, Washington MK, Schwartz DA, Muldoon RL, Herline AJ, Wise PE, Caprioli RM. Proteomic profiling of mucosal and submucosal colonic tissues yields protein signatures that differentiate the inflammatory colitides**.** *Inflamm Bowel Dis* 2011; 17(4):875-83. **IF_{2011} – 4.855.**

143. Seeley EH, Washington MK, Caprioli RM, M'Koma AE. Proteomic Patterns of Colonic Mucosal and Submucosal Tissues Delineates Crohn's Colitis and Ulcerative Colitis. *Proteomics Clin Appl* 2013; 7(7-8):541-9. **IF_{2013} – 1.97**

144. Kurmaeva E, Boktor M, Zhang S, Bao R, Berney S, Ostanin DV. Roles of T cell-associated L-selectin and β7 integrins during induction andregulation of chronic colitis. *Inflamm Bowel Dis.* 2013; 19(12):2547-59. **IF_{2013} – 5.12**

145. Hua, M., Sun, J., Yu, C. Relationship between peripheral lymphocyte function associated antigen-1 and clinical features in patients with inflammatory bowel disease. *Chinese Journal of Gastroenterology* 2013; 18(11):667-671.

146. Theodoratou E, Campbell H, Ventham NT, Kolarich D, Pučić-Baković M, Zoldoš V, Fernandes D, Pemberton IK, Rudan I, Kennedy NA, Wuhrer M, Nimmo E, Annese V, McGovern DP, Satsangi J, Lauc G. The role of glycosylation in IBD. **Nat** *Rev Gastroenterol Hepatol*. 2014; 11(10):588-600. **IF_{2013} – 10.43**

147. Qiongfang R, Chaoli Z, Ziqing Y et al. Role of phosphoinositide 3-kinase/protein kinase B signal pathway in monocyte-endothelial adhesion induced by serum of rats with electrical burn. *Chinese Journal of Burns 2014*; 30(3):237-242.

148. Cui C, Feng H, Shi X, Wang Y, Feng Z, Liu J, Han Z, Fu J, Fu Z, Tong H. Artesunate down-regulates immunosuppression from colorectal cancer Colon26 and RKO cells in vitro by decreasing transforming growth factor β1 and interleukin-10. *Int Immunopharmacol.* 2015 Jul;27(1):110-21. **F_{2014} – 2.47**

149. Zhu Y(1), Feng Y(2), Liu H(3), Ye H(1), Guo C(4), Feng J(1), Dai S(5), Zheng X(1). CD4(+)CD29(+)T cells are blamed for the persistent inflammatory response in ulcerative colitis. *Int J Clin Exp Pathol*. 2015 Mar 1;8(3):2627-37. **IF_{2014} – 1.89**

150. Zucker SD, Vogel ME, Kindel TL, Smith DL, Idelman G, Avissar U, Kakarlapudi G, Masnovi ME. Bilirubin prevents acute DSS-induced colitis by inhibiting leukocyte infiltration and suppressing upregulation of inducible nitric oxide synthase. *Am J Physiol Gastrointest Liver Physiol.* 2015 Nov 15;309(10):G841-54. **F_{2014} – 3.798**

151. Liu J, Liu W, Xie Y, Wang Y, Ouyang X. Adhesion of monocytes to periodontal fibroblasts requires activation of NOD1/2- and TLR4-mediated LFA-1 and VLA-4. *Arch Oral Biol.* 2015 Jun;60(6):834-44. **F_{2014} – 1.735**

152. Lean QY, Gueven N, Eri RD, Bhatia R, Sohal SS, Stewart N, Peterson GM, Patel RP. Heparins in ulcerative colitis: proposed mechanisms of action and potential

reasons for inconsistent clinical outcomes. *Expert Rev Clin Pharmacol* 2015;8(6):795-811 **F_{2014} – 2.18**

153. Karaboga İ, Demirtas S, Karaca T. Investigation of the relationship between the Th17/IL-23 pathway and innate-adaptive immune system in TNBS-induced colitis in rats. *Iranian Journal of Basic Medical Sciences*. 2017; 20(8):870-879. doi:10.22038/IJBMS.2017.9108. **F_{2016} – 1.424**

154. Vogel, M. (2017). Bilirubin modulates leukocyte recruitment to sites of inflammation. (*Electronic Thesis or Dissertation*). Retrieved from https://etd.ohiolink.edu/

155. Song R, Li Y, Hao W, Wang B, Yang L, Xu F. Identification and analysis of key genes associated with ulcerative colitis based on DNA microarray data. *Medicine (Baltimore)*. 2018 ; 97(21):e10658. doi: 10.1097/MD.0000000000010658.

Цитирана статия (публикация № 16):
Gulubova MV, Vlaykova TI, **MANOLOVA IM**, Hadjipetkov PB, Popharitov AI. Implication of adhesion molecules in inflammation of the common bile duct in patients with secondary acute and chronic cholangitis due to biliary obstruction. ***Hepatogastroenterology*** 2008; 55:840-845

Резултатите са цитирани от:

156. Florentin M, Elisaf MS, Mikhailidis DP, Liberopoulos EN. Vitamin D and metabolic syndrome: is there a link? *Curr Pharm Des* 2010; 16(30):3417-34 **IF_{2010} – 4.774**

157. Liberopoulos EN, Florentin M, Elisaf MS, Mikhailidis DP, Tsianos E. Fenofibrate in primary biliary cirrhosis: a pilot study. *The open cardiovascular medicine journal* 2010, 4:120-126..

158. Melamed R, Rosenne E, Benish M, Goldfarb Y, Levi B, Ben-Eliyahu S. The marginating-pulmonary immune compartment in rats: characteristics of continuous inflammation and activated NK cells. *J Immunother* 2010; 33(1):16-29. **IF_{2010} - 3,593**

159. Gupta GS. Selectins and Associated Adhesion Proteins in Inflammatory disorders IN: Animal Lectins: Form, Function and Clinical Applications, pp 991-1026; 11 May 2012 - Springer

160. Krishnan TR, Velusamy P, Srinivasan A, Ganesan T, Mangaiah S, Narasimhan K, Chakrapani LN, J T, Walter CE, Durairajan S, Nathakattur Saravanabavan S, Periandavan K. EGCG mediated downregulation of NF-AT and macrophage infiltration in experimental hepatic steatosis. *Exp Gerontol* 2014; 57:96-103. **IF_{2013} - 3.911**

Цитирана статия (публикация № 17):
Gulubova M, **MANOLOVA I**, Cirovski G, Sivrev D. Recruitment of dendritic cells in human liver with metastases. ***Clin Exp Metastasis*** 2008; 25:777-785

Резултатите са цитирани от:

161. Lipscomb MW, Taylor JL, Goldbach CJ, Watkins SC, Wesa AK, Storkus WJ. DC expressing transgene Foxp3 are regulatory APC. *Eur J Immunol* 2010; 40(2):480-93. **IF_{2010} – 4.942**

162. Zöller M, T Jung - The Colorectal Cancer Initiating Cell: Markers and Their Role in Liver Metastasis IN: *Liver Metastasis: Biology and Clinical Management,* Pnina Brodt (Eds) Springer Science 2011, ISBN: 978-94-007-0291-2, pp 89-127

163. Wu H, Ramanathan RK, Zamboni BA, Strychor S, Ramalingam S, Edwards RP, Friedland DM, Stoller RG, Belani CP, Maruca LJ, Bang YJ, Zamboni WC. Population Pharmacokinetics of Pegylated Liposomal CKD-602 (S-CKD602) in Patients With Advanced Malignancies. *J Clin Pharmacol* 2011; 52(2):180-94. **IF_{2011} – 2.911**

164. Rusu MC, Pop F, Hostiuc S, Curca GC, Jianu AM, Paduraru D. Telocytes form networks in normal cardiac tissues. *Histol Histopathol* 2012; 27(6):807-16. **IF_{2012} – 2.48**

165. Kurmaeva E, Boktor M, Zhang S, Bao R, Berney S, Ostanin DV. Roles of T cell-associated L-selectin and β7 integrins during induction and regulation of chronic colitis. *Inflamm Bowel Dis* 2013; 19(12):2547-59. **IF_{2013} – 5.119**

166. Stefanov I, Vodenicharov A. S-100 Protein-Positive Mast Cells in Canine Paranal Sinus (Sinus paranalis). *Anat Histol Embryol* 2013; 43(5):408-12 **IF_{2013} – 0.882**

Цитирана статия (публикация № 18):
MANOLOVA IM. Anti-Lactoferrin antoibodies in patients with connective tissue diseases. ***Folia Medica,*** 2003;45(4): 25-30.

Резултатите са цитирани от:

167. Raina, A., Greer, J.B., Whitcomb, D.C. Serology in autoimmune pancreatitis. (2008) *Minerva Gastroenterologica e Dietologica*, 54 (4), pp. 375-387.

168. Lutz, H.U., Bogdanova, A. Mechanisms tagging senescent red blood cells for clearance in healthy humans. (2013) *Frontiers in Physiology*, 01/2013; 4:387

169. Gajić-Veljić MD. Antineutrofilna citoplazmatska antitela-značaj za dijagnozu i procenu aktivnosti sistemskog lupusa i lupusa indukovanog lekom. Disertacija 2016, Медицински Факултет, Универзитет у Београду.

170. Shida H, Nakazawa D, Tateyama Y, Miyoshi A, Kusunoki Y, Hattanda F, Masuda S, Tomaru U, Kawakami T, Atsumi T, Ishizu A. The Presence of Anti-Lactoferrin Antibodies in a Subgroup of Eosinophilic Granulomatosis with Polyangiitis Patients and Their Possible Contribution to Enhancement of Neutrophil Extracellular Trap Formation. Front Immunol. 2016 Dec 23;7:636. doi: 10.3389/fimmu.2016.00636. **IF_{2016} – 6.429**

Цитирана статия (публикация № 28):
МАНОЛОВА И., М. Иванова, С. Димитрова. Диагностична стойност на АНА теста върху НЕр-2 при системните заболявания на съединителната тъкан***. Ревматология*** XII, 2004, бр.2-3:47-51.

Резултатите са цитирани от:

171. **Марин Й. Загоров.** "Имунофлуоресцентен метод за АНА с клетъчна линия McCoy-Plovdiv", ДИСЕРТАЦИЯ ЗА НАУЧНАТА И ОБРАЗОВАТЕЛНА СТЕПЕН " ДОКТОР" от Пловдив, 2006г. с.21, с.92, 104.

Цитирана статия (публикация № 32):
Иванова И., **И. МАНОЛОВА** и Р. Стоилов. Феномен на Raynaud и антицентромерни антитела: преглед на литературата и описание на два случая. ***Ревматология*** XIII, 2005, бр.2:27-31.

Резултатите са цитирани от:

172. Lambova, S. Роля на капиляроскопията в ревматологията; The role of capillaroscopy in rheumatology / S. Lambova. // *Revmatologiia*, 16, 2008, N 1-2, ISSN 1310-0505 , с. 17-27, 2 fig. Sum. Bulg., Engl. 82 ref.

173. Lambova, S. et al. Raynaud's phenomenon in common rheumatic diseases; Феномен Raynaud при сравнительно часто встречаемых ревматических заболеваниях / S. Lambova, S. Kuzmanova. // *Folia medica*, 48, 2006, N 3-4, ISSN 0204-8043 , с. 22-28, 2 fig., Sum. Rus., Engl. 35 ref.

174. Стойнева, Зл. Феномен на Рейно. Атланто-Евро-Средиземноморска академия на медицинските науки. С., Издателство „Инфопрес”, 2006, 252 с.

Цитирана статия (публикация № 35)

МАНОЛОВА И., М. Иванова, С. Владева. Диагностична стойност на ANCA теста в клиничната практика. ***Ревматология*** XVI, 2008, бр.3-4:23-29.

Резултатите са цитирани от:

175. Nikolov, K. et al. ANCA при диагнозата на синдрома на churg-strauss; ANCA in the diagnosis of churg-strauss' syndrome / K. Nikolov, M. Baleva. // *Revmatologiia*, 17, 2009, N 1, ISSN 1310-0505, с. 28-30, Sum. Bulg., Engl. 18 ref.

Цитирана статия (публикация № 36)
Иванова М., **И. МАНОЛОВА**, Р. Стоилов Сравнителна стойност на СУЕ и С – реактивния протеин в оценката на болестната активност при анкилозиращия спондилит. ***Ревматология*** XVI, 2008, бр.3-4:46-52.

Резултатите са цитирани от:

176. TROEV, T. et al. Физикална и рехабилитационна медицина в съвременните терапевтични методи за лечение на анкилозиращия спондилит; Physical and rehabilitation medicine in the contempory therapeutic methods of ankylosing spondylitis treatment / T. Troev, M. Georgieva, E. Konakchieva. // *Prevantivna meditsina*, 2, 2013, N 5, ISSN 1314-5681 , с. 28-33, Sum. Bulg., Engl. 22 ref.

Цитирана статия (публикация № 40):
МАНОЛОВА И. Честота и антигенни специфичности на антинуклеарните антитела (АНА) в клиничната практика – анализ за периода 1998-2002. ***Съвременна медицина*** LV, 2004, бр.6:42-28

Резултатите са цитирани от:

177. Марин Й. Загоров. "Имунофлуоресцентен метод за АНА с клетъчна линия McCoy-Plovdiv", ДИСЕРТАЦИЯ ЗА НАУЧНАТА И ОБРАЗОВАТЕЛНА СТЕПЕН " ДОКТОР" от Пловдив, 2006г. с.21, с.87, 104.

Цитирана статия (публикация № 41)
МАНОЛОВА И., В. Цонева, М. Иванова. Сравнителна оценка на два имунометрични метода за определяне на антинуклеарни антитела (АНА). ***Медицински преглед***, 2006, 42 (1) 98-101.

Резултатите са цитирани от:

178. MURDJEVA, M. et al. A comparative study of immunological methods for determination of serum antinuclear antibodies / M. Murdjeva, P. Ryasheva, M. Draganov, L. Paunov. // *Folia medica*, 53, 2011, N 4, ISSN 0204-8043 , c. 21-27, 1 tabl., 2 fig. Sum. Engl. Rus. 23 ref.

Цитирана статия (публикация № 42)
Гълъбова М, **МАНОЛОВА И**, Влайкова Т. Имунохистохимично изследване на дендритни клекти при първичен хепатоцелуларен карцином. ***Съвременна медицина*** LVII, 2006, кн. 5:3-11.

Резултатите са цитирани от:

179. Юл. Р. Ананиев. Дендритни клетки и противотуморен имунитет. *Съвременна медицина*. 2009, том 60, бр.5-6:118-125

Цитирана статия (публикация № 48)
Gulubova M, **MANOLOVA I,** Kyurkchiev D, Julianov A, Altunkova I. Decrease in intrahepatic CD56+ lymphocytes in gastric and colorectal cancer patients with liver metastases. ***APMIS*** 2009;117(12):870-879.

Резултатите са цитирани от:

180. Yuan, S.-X. NKT and NK cells in peripheral blood of colorectal cancer patients after surgery. *Chinese Journal of Cancer Biotherapy* 2010; 17(5):565-567.

181. Berzins SP, Smyth MJ, Baxter AG. Presumed guilty: natural killer T cell defects and human disease. *Nat Rev Immunol* 2011;11(2):131-42 **IF_{2011} – 32.287**

182. Rezaei N, Mahmoudi E, Aghamohammadi A, Das R, Nichols KE. X-linked lymphoproliferative syndrome: a genetic condition typified by the triad of infection, immunodeficiency and lymphoma. *Br J Haematol* 2011;152(1):13-30 **IF_{2011} – 4.941**

183. Levy EM, Roberti MP, Mordoh J. Natural killer cells in human cancer: from biological functions to clinical applications. *J Biomed Biotechnol* 2011; 2011:676198. **IF_{2011} - 2.436**

184. Werner JM, Lang C, Scherer MN, Farkas SA, Geissler EK, Schlitt HJ, Hornung M. Distribution of intrahepatic T, NK and CD3(+)CD56(+)NKT cells alters after liver transplantation: Shift from innate to adaptive immunity? *Transpl Immunol* 2011; 25(1):27-33. **IF_{2011} - 1.459**

185. Zhong-Fu Wu; Tang Suo-Qin; Zhao An-Di; et al. Clinical Applications of NK Cells in Tumor Immunotherapy. *Zhongguo Shengwu Huaxue yu Fenzi Shengwu Xuebao* 2011; 27(12):1088-1093

186. Sasada, T., Suekane, S. Variation of tumor-infiltrating lymphocytes in human cancers: Controversy on clinical significance. *Immunotherapy* 2011; 3 (10):1235-1251. **IF_{2011} - 1.854**

187. Senovilla, L., Vacchelli, E., Galon, J., Adjemian, S., Eggermont, A., Fridman, W.H., Sautès-Fridman, C., Ma, Y., Tartour, E., Zitvogel, L., Kroemer, G., Galluzzi, L. Trial watch prognostic and predictive value of the immune infiltrate in cancer. *OncoImmunology* 2012: 1 (8):1323-1343.

188. Al Omar SY, Marshall E, Middleton D, Christmas SE. Increased numbers but functional defects of CD56+CD3+ cells in lung cancer. *Int Immunol.* 2012; 24(7):409-15. **IF_{2012} - 3.415**

189. Desbois M, Rusakiewicz S, Locher C, Zitvogel L, Chaput N. Natural killer cells in non-hematopoietic malignancies. *Front Immunol* 2012;3:395.

190. Céspedes MA, JA Rodríguez, M Medina et al. Analysis of NK Cells in Peripheral Blood and Tumor Infiltrating Lymphocytes in Cervical Cancer Patients. *Rev Colomb Cancerol* 2012;16(1):16-26

191. Baxevanis CN, Papamichail M, Perez SA. Immune classification of colorectal cancer patients: impressive but how complete? *Expert Opin Biol Ther* 2013; 13(4):517-26. **IF_{2013} – 3.345**

192. Mariani F, Sena P, Pedroni M, Benatti P, Manni P, Di Gregorio C, Manenti A, Palumbo C, de Leon MP, Roncucci L. Th inducing POZ-Kruppel Factor (ThPOK) is a key regulator of the immune response since the early steps of colorectal carcinogenesis. *PLoS One* 2013; 8(1):e54488. **IF_{2013} - 3.73**

193. Liu G, Lu S, Wang X, Page ST, Higano CS, Plymate SR, Greenberg NM, Sun S, Li. Z, Wu JD. Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis. *J Clin Invest* 2013; 123(10):4410-22. **IF_{2013} - 12.812**

194. Gogali, F**.,** Paterakis, G., Rassidakis, G.Z., Liakou, C.I., Liapi, C. CD3-CD16-CD56bright immunoregulatory NK cells are increased in the tumor microenvironment and inversely correlate with advanced stages in patients with papillary thyroid cancer. (2013) *Thyroid* 2013; 23(12):1561-1568. **IF_{2013} - 3.544**

195. Li XH, He F, Yan SM, Li Y, Cao Y, Huang CY, Zhou ZW.Increased expression of stomatin-like protein 2 (STOML2) predicts decreased survival in gastric adenocarcinoma: a retrospective study. *Med Oncol* 2014; 31(1):763. **IF_{2013} - 2.147**

196. Berzins SP, DS Ritchie. Natural killer T cells: drivers or passengers in preventing human disease? *Nat Rev Immunol* 2014; 14(9):640-6. **IF_{2013} – 33.129**

197. Sconocchia G, Eppenberger S, Spagnoli GC, Tornillo L et al. NK cells and T cells cooperate during the clinical course of colorectal cancer. *OncoImmunology*, 2014; 3(8): e952197

198. Chen X, Lu P, Chen L, Yang SJ, Shen HY, Yu DD, Zhang XH, Zhong SL, Zhao JH, Tang JH. Perioperative propofol-paravertebral anesthesia decreases the metastasis and progression of breast cancer. *Tumour Biol* 2015; 36(11): 8259-66. **IF_{2014} – 3.611**

199. Yan S, He F, Luo R, Wu H, Huang M, Huang C, Li Y, Zhou Z. Decreased expression of BRCA1-associated protein 1 predicts unfavorable survival in gastric adenocarcinoma. *Tumour Biol* 2015 Nov 26. [Epub ahead of print] **IF_{2014} – 3.611**

200. Tanis E, Julié C, Emile JF, Mauer M, Nordlinger B, Aust D, Roth A, Lutz MP, Gruenberger T, Wrba F, Sorbye H, Bechstein W, Schlag P, Fisseler A, Ruers T. Prognostic impact of immune response in resectable colorectal liver metastases treated by surgery alone or surgery with perioperative FOLFOX in the randomised EORTC study 40983. *Eur J Cancer* 2015; 51(17): 2708-17. **IF_{2014} – 5.417**

201. Bigley AB, Simpson RJ. NK cells and exercise: implications for cancer immunotherapy and survivorship. *Discov Med* 2015; 19(107): 433-45. **IF_{2014} – 5.626**

202. Juricke M. Die Rolle von regulatorischen T-Zellen bei Tumorerkrankungen. Dissertation. Christian-Albrechts-Universitat zu Kiel, Medizinische Fakultät, urn:nbn:de:gbv:8-diss-171573, 2015

203. Al-dulaimy NH, Al-Araji SM, Hassan AJ. Estimating CD56 and Perforin in Rats Primed by Breast Cancer Cell Line T47D. Journal *of Babylon University/Pure and Applied Sciences* 2016; 5(24):1214-1220

204. Vyčítal O. Molecular biologic principles of progression of colorectal carcinoma and tehir impact on individualized oncosurgical treatment. Disertation Theses. Faculty of Medicine in Pilsen, 2017

205. Faas, Marijke M. De Vos P. Uterine NK cells and macrophages in pregnancy. *Placenta* 2017; 56:44 – 52. DOI: https://doi.org/10.1016/j.placenta.2017.03.001 **IF_{2016} – 2.759**

206. Li, X., Dai, D., Song, X., Liu, J., Zhu, L., Zhu, X. ... Xu, W. (2017). A different representation of natural T cells and natural killer cells between tumor-infiltrating and periphery lymphocytes in human hepatocellular carcinoma. *Oncology Letters* 2017; 13 (5): 3291-3298. https://doi.org/10.3892/ol.2017.5808 **IF_{2016} – 1.39**

207. Grizzi, F., Basso, G., Borroni, E.M. et al. Evolving notions on immune response in colorectal cancer and their implications for biomarker development. *Inflamm. Res* 2018; 67: 375. https://doi.org/10.1007/s00011-017-1128-1 **IF_{2016} – 2.659**

208. Bigley A.B., Baker F.L., Spielmann G., Simpson R.J. (2018) Aging Immunity and the Impact of Physical Exercise. In: Fulop T., Franceschi C., Hirokawa K., Pawelec G. (eds) Handbook of Immunosenescence. Springer, Cham

209. Du Y, Wei Y. Therapeutic Potential of Natural Killer Cells in Gastric Cancer. *Frontiers in Immunology*, 21 January 2019, DOI: 10.3389/fimmu.2018.03095 **SJR – 5.**

210. Li Hongcai MM; Zhao, Yan MM; Zheng, Fengying MM. Prognostic significance of elevated preoperative neutrophil-to-lymphocyte ratio for patients with colorectal cancer undergoing curative surgery: A meta-analysis. *Medicine*, 2019; 98(3): p e14126, doi: 10.1097/MD.0000000000014126 **IF_{2018} – 2.028**

211. Chen X, Zhang W, Qian D et al. Chemoradiotherapy-Induced CD4+ and CD8+ T-Cell Alterations to Predict Patient Outcomes in Esophageal Squamous Cell Carcinoma. *Frontiers in Oncology* 9, February 2019, DOI: 10.3389/fonc.2019.00073 **SJR – 4.45.**

212. Degos C, Heinemann M, Barrou J, Boucherit N, Lambaudie E, Savina A, Gorvel L, Olive. Endometrial Tumor Microenvironment Alters Human NK Cell Recruitment, and Resident NK Cell Phenotype and Function. *Front. Immunol.,* 26 April 2019, https://doi.org/10.3389/fimmu.2019.00877 **SJR – 2.803**

213. Pernot, S., Terme, M., Radosevic-Robin, N. et al. Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance. *Gastric Cancer* (2019). https://doi.org/10.1007/s10120-019-00983-3 **IF_{2018} – 5.045**

214. Portales-Cervantes, L.; Dawod, B.; Marshall, J.S. Mast Cells and Natural Killer Cells—A Potentially Critical Interaction. *Viruses* 2019, *11*, 514. **SJR – 1.812**

Цитирана статия (публикация № 49)

Gulubova M, **MANOLOVA I**, Ananiev J, Julianov A, Yovchev Y, Peeva K. Role of TGF-β1, its receptor TGFβRII and Smad proteins in the progression of colorectal cancer. ***Int J Colorectale Disease*** 2010; 25(5):591-599

Резултатите са цитирани от:

215. Li Y, Zhu X, Zeng Y, Wang J, Zhang X, Ding YQ, Liang L. FMNL2 enhances invasion of colorectal carcinoma by inducing epithelial-mesenchymal transition**.** *Mol Cancer Res* 2010; 8(12):1579-90. **IF_{2010}- 4.35**

216. Migliore L, Migheli F, Spisni R, Coppedè F. Genetics, cytogenetics, and epigenetics of colorectal cancer. *J Biomed Biotechnol* 2011; 2011:792362 **IF_{2011} - 2.436**

217. Lee KW, Kim SJ, Park JB, Lee KJ. Relationship between depression anxiety stress scale (DASS) and urinary hydroxyproline and proline concentrations in hospital workers. *J Prev Med Public Health* 2011; 44(1):9-13.

218. Harrison S, Benziger H. The molecular biology of colorectal carcinoma and its implications: a review. *Surgeon* 2011 Aug;9(4):200-10. **IF_{2011} - 1.97**

219. Stingo FC, Vannucci M. Variable selection for discriminant analysis with Markov random field priors for the analysis of microarray data. *Bioinformatics* 2011 Feb; 27(4):495-501. **$IF2_{011}$ – 5.47**

220. Lim YH, Jeong YS, Kim SK, Kim DH, Yun DH, Yoo SD, Kim HS, Baik HH. Association between TGFBR2 gene polymorphism (rs2228048, Asn389Asn) and intracerebral hemorrhage in Korean population. Immunol Invest 2011; 40(6):569-80 **IF_{2011} - 1.47**

221. Golmoghaddam H, Pezeshki AM, Ghaderi A, Doroudchi M. CD1a and CD1d genes polymorphisms in breast, colorectal and lung cancers. *Pathol Oncol Res* 2011;1 7(3):669-75 **IF_{2011} – 1.56**

222. Khanh DT, E Mekata, K Mukaisho, et al. Prognostic role of $CD10^+$ myeloid cells in association with tumor budding at the invasion front of colorectal cancer. *Cancer Science* 2011; 102(9):1724–1733 **IF_{2011} - 3.48**

223. Slattery, M.L., Lundgreen, A., Herrick, J.S., Wolff, R.K., Caan, B.J. Genetic variation in the transforming growth factor-β signaling pathway and survival after diagnosis with colon and rectal cancer. *Cancer* 2011; 117(18):4175-4183

224. Cui G, Shi Y, Cui J, Tang F, Florholmen J. Slattery ML, Lundgreen A, Wolff RK, Herrick JS, Caan BJ. Genetic variation in the transforming growth factor-β-signaling pathway, lifestyle factors, and risk of colon or rectal cancer. *Dis Colon Rectum* 2012; 55(5):532-40. **IF_{2012} – 5.2**

225. Cui, G., Shi, Y., Cui, J., Tang, F., Florholmen, J. Immune microenvironmental shift along human colorectal adenoma-carcinoma sequence: is it relevant to tumor development, biomarkers and biotherapeutic targets? *Scand J Gastroenterol* 2012; 47(4):367-77. **IF_{2012} - 2.33**

226. Joyce T, Oikonomou E, Kosmidou V, Makrodouli E, Bantounas I, Avlonitis S, Zografos G, Pintzas A. A molecular signature for oncogenic BRAF in human colon cancer cells is revealed by microarray analysis. *Curr Cancer Drug Targets* 2012; 12(7):873-98. **IF_{2012} - 4.327**

227. Li, Jin; Ye, Lin; G. Jiang, Wen. Repulsive Guidance Molecules (RGMs) and Their Potential Implication in Cancer as Co-receptor of BMPs**.** *Current Signal Transduction Therapy* 2012; 7(2): 149-160. **IF_{2012} - 0.5**

228. Kang HJ, Kim EJ, Kim BG, You CH, Lee SY, Kim DI, Hong YS. Quantitative analysis of cancer-associated gene methylation connected to risk factors in Korean colorectal cancer patients. *J Prev Med Public Health* 2012; 45(4):251-8.

229. Choe BK, SK Kim, HJ Park, HK Park, KH Kwon. Polymorphisms of TGFBR2 contribute to the progression of papillary thyroid carcinoma**.** *Mol Cell Toxicol* 2012:1-8 **IF_{2012} - 0.88**

230. Pyatnitskiy, M.A., Shkrob, M.A., Daraselia, N.D., Kotelnikova, E.A. (Book Chapter) Sub-Network enrichment and cluster analysis reveal possible pathways for cetuximab sensitivity. IN: Yuryev A and Daraselia N (Eds) "From Knowledge Networks to Biological Models", Bentham Science 2012, ISBN 978-1-60805-436-7, pp. 151-172.

231. Khong, T.L., Thairu, N., Larsen, H., Dawson, P.M., Kiriakidis, S., Paleolog, E.M. Identification of the angiogenic gene signature induced by EGF and hypoxia in colorectal cancer. *BMC Cancer*, 2013; 13:518. **IF_{2013} - 3.333**

232. Ramamoorthi G, N Sivalingam. Molecular mechanism of TGF-β signaling pathway in colon carcinogenesis and status of curcumin as chemopreventive strategy. *Tumour Biol* 2014; 35(8):7295-305 **IF_{2013} – 2.52**

233. Chun HK, Jung KU, Choi YL, Hong HK, Kim SH, Yun SH, Kim HC, Lee WY, Cho YB. Low Expression of Transforming Growth Factor Beta-1 in Cancer Tissue Predicts a Poor Prognosis for Patients with Stage III Rectal Cancers. *Oncology* 2014; 86(3):159-169. **IF_{2013} – 2.165**

234. Fu Y, Liu X, Zhou N, Du L, Sun Y, Zhang X, Ge Y. MicroRNA-200b stimulates tumour growth in TGFBR2-null colorectal cancers by negatively regulating p27/kip1. *J Cell Physiol* 2014; 229(6):772-82. **IF_{2013} - 4.22**

235. Fortini BK, Tring S, Plummer SJ, Edlund CK, Moreno V, Bresalier RS, Barry EL, Church TR, Figueiredo JC, Casey G. Multiple functional risk variants in a SMAD7 enhancer implicate a colorectal cancer risk haplotype. *PLoS One* 2014; 6;9(11):e111914. **IF_{2013} – 3.73**

236. Brix JA, Die Rolle des Chromosom 18 Verlustes fur neuroendokrine Tumore des Ileum. Disertatio zzur Erlangung des Doktorgrades der Medizin. Der Medizinischen Fakultat der Eberhard Karls Universitat zu Tubingen, 2015

237. Hwang JH, TW Kang, YT Kim, SO Park. Analysis on Co-channel Interference of Human Body Communication Supporting IEEE 802.15.6 BAN Standard. *ETRI* 2015; 37(3): 439-449.

238. Shi Y, Z Li, W Zheng, X Liu, C Sun, JB Laugsand, Z Liu… Changes of immunocytic phenotypes and functions from human colorectal adenomatous stage to cancerous stage: Update. *Immunobiology* 2015; 220(10): 1186-1196 **IF_{2014} – 3.044**

239. Lian W, D Ma, P Dong. Chronic Inflammation and Colorectal Cancer Microenvironment. *Advances in Clinical Medicine* 2015; 5(4): 199-266 **IF_{2014} – 2.47**

240. Voorneveld PW, Jacobs RJ, Kodach LL, Hardwick JC. A Meta-Analysis of SMAD4 Immunohistochemistry as a Prognostic Marker in Colorectal Cancer. *Transl Oncol* 2015; 8(1): 18-24. **IF_{2014} – 2.077**

241. Cui C, Feng H, Shi X, Wang Y, Feng Z, Liu J, Han Z, Fu J, Fu Z, Tong H. Artesunate down-regulates immunosuppression from colorectal cancer Colon26 and RKO cells in vitro by decreasing transforming growth factor β1 and interleukin-10. Int *Immunopharmacol* 2015; 27(1): 110-21. IF2014 – 2.472

242. Abd El-Fattah, A.A., Sadik, N.A.H., Shaker, O.G. et al. Are SMAD7 rs4939827 and CHI3L1 rs4950928 polymorphisms associated with colorectal cancer in Egyptian patients? *Tumor Biol* 2016; 37: 9387. https://doi.org/10.1007/s13277-016-4813-8 **IF_{2016} – 2.926**

243. Yi H, Geng L, Black A, Talmon G, Berim L, Wang J. The miR-487b-3p/GRM3/TGFβ signaling axis is an important regulator of colon cancer

tumorigenesis. *Oncogene* 2017; 36(24):3477-3489. doi: 10.1038/onc.2016.499 **IF_{2016} – 7.519**

244. Witkowska M, A Majchrzak, B Cebula-Obrzut et al. The distribution and potential prognostic value of SMAD protein expression in chronic lymphocytic leukemia. *Tumor Biology* 2017; March 28 https://doi.org/10.1177/1010428317694551 **IF_{2016} – 3.65**

245. Chen X, Zhuo-qun Chen, Shui-lian Zhu et al. Prognostic value of transforming growth factor-beta in patients with colorectal cancer who undergo surgery: a meta-analysis. *BMC Cancer*, 2017; 17(1):240 **IF_{2016} – 3.288**

246. Chen J, Huang C, Zhu D, Shen P, Duan Y, Wang J, Yang C, Wu L. Chinese 1 strain of Toxoplasma gondii excreted-secreted antigens negatively modulate Foxp3 via inhibition of the TGFßRII/Smad2/Smad3/Smad4 pathway. *J Cell Mol Med* 2017; 21(9):1944-1953. doi: 10.1111/jcmm.13115 **IF_{2016} – 4.499**

247. Harrison S, Benziger H. Colorectal Carcinogenic Pathways and Chemotherapeutic Responsiveness: A Review. *Journal of Digestive Disorders And Diagnosis 2017* - 1(2):13-27.

248. Konishi, Y., Kawamata, F., Nishihara, H. et al. Tumor budding and human chorionic gonadotropin-β expression correlate with unfavorable patient outcome in colorectal carcinoma. *Med Oncol* 2018; 35: 104._https://doi.org/10.1007/s12032-018-1164-x **IF_{2016} – 2.634**

249. Kawamata F, Nishihara H, Homma S, Kato Y, Tsuda M, Konishi Y, Wang L, Kohsaka S, Liu C, Yoshida T, Tanino M, Tanaka S, Kawamura H, Kamiyama T, Taketomi A. Chorionic Gonadotropin-β Modulates Epithelial-Mesenchymal Transition in Colorectal Carcinoma Metastasis. *Am J Pathol.* 2018; 188(1):204-215. doi: 10.1016/j.ajpath.2017.08.034. **IF_{2016} – 4.057**

250. Ganesan, R. & Sivalingam, N. Transforming Growth Factor Beta 2 Inhibits Growth and Proliferation Potential of Smad4 and p53 Mutated Human Colon Adenocarcinoma Cells. *Pathol. Oncol. Res* 2018 https://doi.org/10.1007/s12253-018-0423-7 **IF_{2016} – 1.736**

251. El-Fattah AAA, Sadik NAH, Shaker OG, and Kamal AM. Single Nucleotide Polymorphism in SMAD7 and CHI3L1 and Colorectal Cancer Risk. *Mediators of Inflammation*, 2018(1):1-23, https://doi.org/10.1155/2018/9853192. **IF_{2017} – 3.549**

252. Zhang F, Ren CC, Liu L, Chen YN, Yang L, Zhang XA. HOXC6 gene silencing inhibits epithelial-mesenchymal transition and cell viability through the TGF-β/smad signaling pathway in cervical carcinoma cells. *Cancer Cell Int.* 2018 Dec 12;18:204. doi: 10.1186/s12935-018-0680-2. **IF_{2017} – 3.96**

253. Soleimani A, Pashirzad M, Avan A, Ferns GA, Khazaei M, Hassanian SM. Role of the transforming growth factor-β signaling pathway in the pathogenesis of colorectal cancer. *J Cell Biochem.* 2019;120(6):8899-8907 https://doi.org/10.1002/jcb.28331 IF_{2018} – 3.61

254. Dai Guoliang, Bingting Sun, Tao Gong, Zihao Pan, Qinghai Meng, Wenzheng Ju. Ginsenoside Rb2 inhibits epithelial-mesenchymal transition of colorectal cancer cells by suppressing TGF-β/Smad signaling. *Phytomedicine* 2019; 56:126-135 https://doi.org/10.1016/j.phymed.2018.10.025.

255. Jiang Z, Cao Q, Dai G, Wang J, Liu C, Lv L, Pan J Celastrol inhibits colorectal cancer through TGF-β1/Smad signaling. *OncoTargets and Therapy*, 2019; 12:509-518 **IF_{2018} – 2.656**

256. Y Yao, Z Zhou, L Li, J Li, L Huang, J Li, C Qi, L Zheng. Activation of Slit2/Robo1 Signaling Promotes Tumor Metastasis in Colorectal Carcinoma through

Activation of the TGF-β/Smads Pathway. *Cells* 2019, *8*(6), 635; https://doi.org/10.3390/cells8060635

Цитирана статия (публикация № 50)
Ananiev J. R, M. V. Gulubova, **I. M. MANOLOVA**. Prognostic significance of CD83 positive tumor-infiltrating dendritic cells and expression of TGF-beta 1 in human gastric cancer. ***Hepatogastroenterology*** 2011; 58(110-111):1834-1840

Резултатите са цитирани от:

257. Tewari, M., Sahai, S., Mishra, R.R., Shukla, S.K., Shukla, H.S. Dendritic cell therapy in advanced gastric cancer: A promising new hope? *Surgical Oncology* 2012; 21(3):164-171. **IF_{2012} - 2.444**

258. Ding, R., Yu, Y.-H. New advances in HER2 testing in gastric cancer. *World Chinese Journal of Digestology* 2013; 21(36):4098-4103.

259. Liu, Y., Sæter, T., Vlatkovic, L., Servoll, E., Waaler, G., Axcrona, U., Giercksky, K.-E., Nesland, J.M., Suo, Z.-H., Axcrona, K. Dendritic and lymphocytic cell infiltration in prostate carcinoma. *Histology and Histopathology* 2013; 28(12):621-1628. **IF_{2013} - 2.281**

260. El Deeb, N.M.F., Mehanna, R.A. Assessment of maturation status of tumor-infiltrating dendritic cells in invasive ductal carcinoma of the breast: Relation with vascular endothelial growth factor expression. *Turk Patoloji Dergisi/Turkish Journal of Pathology* 2013; 29(3):193-200.

261. Kapoor, S. CD83 antigen expression and its role in the progression of systemic malignancies. *Sao Paulo Medical Journal* 2013; 131(2):137-138. **IF_{2013} - 0.588**

262. Aerts, J.G., Hegmans, J.P. Tumor-specific cytotoxic t cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer. *Cancer Research* 2013; 73(8):2381-2388. **IF_{2013} - 8.65**

263. Chang W-W, L, Hong Su, Yao Y-S. An updated meta-analysis of transforming growth factor-β1 gene: three polymorphisms with gastric cancer. *Tumor Biology* 2014; 35(4):2837-2844 **IF_{2013} - 2.518**

264. Wu, F.-L., Li, G.-H. Dendritic cell vaccines in gastric cancer immunotherapy. *World Chinese Journal of Digestology*, 2014; 22 (1):46-52.

265. Sim GC, Chacon J, Haymaker C, Ritthipichai K, Singh M, Hwu P, Radvanyi L. Tumor-infiltrating lymphocyte therapy for melanoma: rationale and issues for further clinical development. *BioDrugs* 2014 Oct;28(5):421-37. **IF_{2013} – 2.809**

266. Bhargava, A., Bunkar, N., Khare, N.K., Mishra, D., Mishra, P.K. Nanoengineered strategies to optimize dendritic cells for gastrointestinal tumor immunotherapy: From biology to translational medicine. *Nanomedicine* 2014; 9 (14), pp. 2187-2202. **IF_{2013} – 5.26**

267. Cai, T.-T., Yan, L.-P., et al. Antitumor effects of cisplatin implants against human gastric cancer in nude mice. *World Chinese Journal of Digestology* 2014; (20):2817-2825

268. Li, R.-L., Zhou, S., Qin, J., Liang, C.-M., Luo, G.-R. Effect of administration of BMDC vaccine sensitized by heat shocked hepal-6 cell proteins on intratumoral CD25+Foxp3+ tregs in mouse hepatocellular carcinoma. *World Chinese Journal of Digestology* 2014; 22(15):2081-2090.

269. Chang, W.-J., Du, Y., Zhao, X., Ma, L.-Y., Cao, G.-W. Inflammation-related factors predicting prognosis of gastric cancer. *World Journal of Gastroenterology* 2014; 20(16):4586-4596. **IF_{2013} – 2.547**

270. Marabelle, A., Kohrt, H., Caux, C., Levy, R. Intratumoral immunization: A new paradigm for cancer therapy. *Clinical Cancer Research* 2014; 20(7):1747-1756 **IF_{2013} – 7.837**

271. Cai, T.-T., Yan, L.-P., Li, H. Effect of cisplatin implantation on human gastric carcinoma xenograft growth in nude mice and tumor expression of SYK and HER2. *World Chinese Journal of Digestology* 2014; (19):2734-2739

272. Sim GC, Chacon J, Haymaker C, Ritthipichai K, Singh M, Hwu P, Radvanyi L. Tumor-infiltrating lymphocyte therapy for melanoma: rationale and issues for further clinical development. *BioDrugs* 2014; 28(5): 421-37. **IF_{2014} – 2.99**

273. Kloß A. Einfluss von klarzelligen Nierenkarzinomzellen auf die immunmodulatorischen Fähigkeiten von humanen 6-sulfo LacNAc+ dendritischen Zellen. Dissertation, 2015, Institut für Immunologie der Technischen Universität Dresden,

274. Becht E, NA Giraldo, C Germain, A de Reyniès et al. Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers. *Advances in Immunology* 2016 130:95-190 **IF_{2014} – 5.962**

275. Rami F, H Mollainezhad, M Salehi. Induced Pluripotent Stem Cell as a New Source for Cancer Immunotherapy. *Genetics Research International* Volume 2016 (2016), Article ID 3451807, http://dx.doi.org/10.1155/2016/3451807 **IF_{2014} – 1.468**

276. Ma H-Y, Liu X-Z, Liang C-M. Inflammatory microenvironment contributes to epithelial-mesenchymal transition in gastric cancer. *World Journal of Gastroenterology* 2016;22(29):6619-6628. doi:10.3748/wjg.v22.i29.6619.

277. Abozeid M, Antonio Rosato, and Roberta Sommaggio, "Immunotherapeutic Strategies for Gastric Carcinoma: A Review of Preclinical and Clinical Recent Development," *BioMed Research International* 2017, Article ID 5791262, 13 pages, 2017. https://doi.org/10.1155/2017/5791262. **SJR – 2.17**

278. Wang D, DuBois R. Role of prostanoids in gastrointestinal cancer. *Journal of Clinical Investigation*. 2018; 128(7):2732-2742. DOI:10.1172/JCI97953. **IF_{2017} – 13.251**

279. Dolcetti R., De Re V. (2019) Immunomodulation and Immunotherapy for Gastric Cancer. In: Canzonieri V., Giordano A. (eds) Gastric Cancer In The Precision Medicine Era. Current Clinical Pathology. Humana, Cham

---

Цитирана статия (публикация № 51)

Ananiev J, Gulubova M, **MANOLOVA I,** Tchernev G. Prognostic significance of HER2/neu expression in gastric cancer. ***Wien Klin Wochenschr.*** 2011; 123(13-14):450-454

Резултатите са цитирани от:

280. Cho J, Jeong J, Sung J, Sung CO, Kim KM, Park CK, Choi MG, Sohn TS, Bae JM, Kim S. A large cohort of consecutive patients confirmed frequent HER2 positivity in gastric carcinomas with advanced stages. *Ann Surg Oncol* 2013; 20(3 suppl):S477-484 **IF_{2013} - 4.12**

281. Deschoolmeester V, F Lardon, P Pauwels, M Peeters. Biomarkers in gastrointestinal cancer: Focus on colon, pancreatic and gastric cancer. IN: Tapan Khan (Ed.) *"Biomarker",* InTech 2012; ISBN: 978-953-51-0577-0; pp 49-76.

282. Sohal D, Sepulveda AR. Sun W. Targeted therapies and molecular diagnostics on gastrointestinal cancers. IN: Seulveda AR and Lynch JP (Eds.) *"Mol Pathology Neoplastic Gastrointestinal Disease"*, Springer US 2013, ISBN: 978-1-4614-6014-5; pp 33-41.

283. Gencer D, Al-Batran SE, Dada R, et al. Metastatic esophagogastric adenocarcinoma: trends in first-line treatment and predictive factors for the implementation of HER2 testing in clinical practice during the first year after trastuzumab market approval. *J Cancer Res Clin Oncol* 2013; 139(2):337-45. **IF_{2013} - 2.91**

284. de Mello RA, Marques AM, Araújo A. HER2 therapies and gastric cancer: a step forward. *World J Gastroenterol* 2013; 19(37):6165-9 **IF_{2013} - 2.55**

285. Luis M, Tavares A, Carvalho LS, Lara-Santos L, Araújo A, de Mello RA. Personalizing therapies for gastric cancer: molecular mechanisms and novel targeted therapies. *World J Gastroenterol* 2013; 19(38):6383-97. **IF_{2013} - 2.55**

286. He, C., Bian, X.-Y., Ni, X.-Z., Shen, D.-P., Shen, Y.-Y., Liu, H., Shen, Z.-Y., Liu, Q. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer. *World J Gastroenterol* 2013; 19(14):2171-2178. **IF_{2013} - 2.55**

287. Roa, I., de Toro, G., Schalper, K., de Aretxabala X Churi, C., Javle, M. Overexpression of the HER2/neu Gene: A New Therapeutic Possibility for Patients With Advanced Gallbladder Cancer. *Gastrointest Cancer Res* 2014; 7(2):42-8.

288. Huang, L., Li, G.-Q., Mao, Z.-J., Zhong, Y. Expression of RNF180 and RECK in gastric carcinoma. *World Chinese Journal of Digestology* 2014; 22(24):3660-3664

289. Tas F, Yasasever CT, Karabulut S, Tastekin D, Duranyildiz D. Serum transforming growth factor-beta1 levels may have predictive and prognostic roles in patients with gastric cancer. *Tumour Biol* 2014 Nov 13. [Epub ahead of print] **IF_{2014} – 2.518**

290. Baykara M, Benekli M, Ekinci O, Irkkan SC, Karaca H, Demirci U, Akinci MB, Unal OU, Dane F, Turkoz FP, Balakan O, Eser EP, Ozturk SC, Ozkan M, Oksuzoglu B, Sevinc A, Demir N, Harputluoglu H, Yalcin B, Coskun U, Uner A, Ozet A, Buyukberber S; Anatolian Society of Medical Oncology (ASMO). Clinical Significance of HER2 Overexpression in Gastric and Gastroesophageal Junction Cancers. *J Gastrointest Surg* 2015; 19(9): 1565-71.

291. Celli R, M Colunga, N Patel, M Djekidel. Metabolic Signature on 18F-FDG PET/CT, HER2 Status, and Survival in Gastric Adenocarcinomas. *J Nucl Med Technol* 2016; 44(4):234-238.

292. Dubinina VG, AA Mashukov et al. Molecular genetic characteristics of gastric cancers from the surgeon's point of view. *Journal of Education, Health and Sport* 2016; 6(11): 592-621

293. Kirkilevsky SI, AG Lurín, VG Dubinina. Some novel ways of gastric cancer patients treatment personification. *Journal of Education, Health and Sport* 2017; 7(5):516-538.

294. Wu H, Zhenzhai Cai, Guangrong Lu, Shuguang Cao, He Huang, Yi Jiang, and Dr. Weijian Sun. Impact of c-erbB-2 Protein on 5-year Survival Rate of Gastric Cancer Patients after Surgery: A Cohort Study and Meta-analysis. *Tumori Journal* 2017; 103(3): 249 – 254 **IF_{2016} – 1.233**

295. Deng J., Wang J., Liang H. (2019) Staging of Gastric Cancer: Current Revision and Future Proposal. In: Noh S., Hyung W. (eds) *Surgery for Gastric Cancer*. Springer, Berlin, Heidelberg

---

Цитирана статия (публикация № 52)

Ananiev J, Gulubova M, Tchernev G, Penkova M, Miteva R, Julianov A, **MANOLOVA I.** Relation between Transforming Growth Factor-β1 expression, its receptor and clinicopathological factors and survival in HER2-negative gastric cancers. ***Wien Klin Wochenschr***. 2011; 123(21-22):668-673.

Резултатите са цитирани от:

296. Lastraioli E, Romoli MR, Arcangeli A. Immunohistochemical biomarkers in gastric cancer research and management. *Int J Surg Oncol* 2012; 2012:868645

297. Liu X, Tang X, Zhang S, Wang Y, Wang X, Zhao C, Luo B. Methylation and Expression of Retinoblastoma and Transforming Growth Factor-β1 Genes in Epstein-Barr Virus-Associated and -Negative Gastric Carcinomas. *Gastroenterol Res Pract* 2012; 2012:906017. **IF_{2012} -0.978**

298. Docea, A.O., Mitruţ, P., Grigore, D., Pirici, D., Călina, D.C., Gofiţă, E.Immunohistochemical expression of TGF beta (TGF-β), TGF beta receptor 1 (TGFBR1), and Ki67 in intestinal variant of gastric adenocarcinomas. Romanian Journal of Morphology and Embryology 2012; 53 (3 SUPPL.):683-692. **IF_{2012} - 0.523**

299. Neel JC, Humbert L, Lebrun JJ. The dual role of TGFβ in human cancer: from tumor suppression to cancer metastasis. *MSA* 2012; 1(3):2-27.

300. Ma GF, Miao Q, Zeng XQ, Luo TC, Ma LL, Liu YM, Lian JJ, Gao H, Chen SY. Transforming growth factor-β1 and -β2 in gastric precancer and cancer and roles in tumor-cell interactions with peripheral blood mononuclear cells in vitro. *PLoS One* 2013**;** 8(1):e54249. **IF_{2013} – 3.73**

301. Jiao F, Jin Z, Wang L, Wang L. Research and clinical applications of molecular biomarkers in gastrointestinal carcinoma. *Biomedical Reports* 2013; 1(6): 819-827

302. Chang W-W, L, Hong Su, Yao Y-S. An updated meta-analysis of transforming growth factor-β1 gene: three polymorphisms with gastric cancer. *Tumor Biology* 2014; 35(4):2837-44. **IF_{2013}- 2.518**

303. Choi YJ, Kim N, Shin A, Lee HS, Nam RH, Chang H, Shin CM, Park YS, Lee DH, Park JH, Jung HC. Influence of TGFB1 C-509T polymorphism on gastric cancer risk associated with TGF-β1 expression in the gastric mucosa. *Gastric Cancer* 2015; 18(3):526-537 **IF_{2013} - 3.989**

304. Zutter MM, Bloom KJ, Cheng L, Hagemann IS, Kaufman JH, Krasinskas AM, Lazar AJ, Leonard DG, Lindeman NI, Moyer AM, Nikiforova MN, Nowak JA, Pfeifer JD, Sepulveda AR, Willis JE, Yohe SL. The Cancer Genomics Resource List 2014. *Arch Pathol Lab Med* 2015; 139(8):989-1008. **IF_{2014} – 2.84**

305. Tas F, Yasasever CT, Karabulut S, Tastekin D, Duranyildiz D. Serum transforming growth factor-beta1 levels may have predictive and prognostic roles in patients with gastric cancer. *Tumour Biol* 2015;36(3): 2097-103. **IF_{2014}- 2.518**

306. Atwa HAEA and Arafa SAA. Significance of TGF-β1 and Catheps in E expression in gastric adenocarcinoma and precancerouslesions. *Journal of American Science* 2016; 12(5):59-67 **IF_{2014}- 2.917**

307. Shehata HH, Abou Ghalia AH, Elsayed EK, Ahmed Said AM, Mahmoud SS. Clinical significance of high levels of survivin and transforming growth factor beta-1

proteins in aqueous humor and serum of retinoblastoma patients. *J AAPOS* 2016; 20(5):444.e1-444.e9. **IF_{2016}- 0.997**

308. Yen E-Y, Miaw S-C, Yu J-S, Lai I-R. Exosomal TGF-β1 is correlated with lymphatic metastasis of gastric cancers. *American Journal of Cancer Research* 2017;7(11):2199-2208 . **IF_{2016}- 3.264**

Цитирана статия (публикация № 53)

Stoilov R, Ivanova M, Garbeva K, Marinova N, **MANOLOVA I**, Kalitchin ZH. Evaluation of lubrication and friction in knee joint attacked by osteoarthritisthreated with Ostenil, Ostenil Plus, Yaral Forte and Durolane. ***J Balk Trib Assoc.*** 2011; 17(3):456-461.

Резултатите са цитирани от:

309. Sheytanov, I., Petranova, Tz., Monov, S., Batalov, A. Musculoskeletal ultrasonography in the assessment of patients with knee osteoarthritis.(2013) *Journal of the Balkan Tribological Association*, 2013; 19 (2), pp. 265-273. **IF_{2013} - 0,318**

Цитирана статия (публикация № 54)

Miteva LD, **IM MANOLOVA**, MG Ivanova, RK Rashkov, RM Stoilov,, MV Gulubova, SA. Stanilova. Functional genetic polymorphisms in interleukin-12B gene in association with systemic lupus erythematosus. ***Rheumatol Int*** 2012; 32:53-59

Резултатите са цитирани от:

310. Haralambieva IH, Ovsyannikova IG, Kennedy RB, Vierkant RA, Pankratz VS, Jacobson RM, Poland GA. Associations between single nucleotide polymorphisms and haplotypes in cytokine and cytokine receptor genes and immunity to measles vaccination. *Vaccine* 2011; 29(45):7883-95. **IF_{2011} – 3.77**

311. Szperl A**,** Saavalainen P, Weersma RK, Lappalainen M, Paavola-Sakki P, Halme L, Färkkilä M, Turunen U, Kontula K, Ponsioen CY, Wijmenga C, van Diemen CC. Functional polymorphism in IL12B promoter site is associated with ulcerative colitis. *Inflammatory Bowel Diseases* 2011; 17(6), E38-E40. **IF_{2011} – 4.855**

312. Suresh A, S. Priya, M. Vannan, K. Dhanya, V. Kekatpure. P48. Salivary biomarkers for the diagnosis and prognosis of oral quamous cell carcinoma. *Oral Oncology* 2011; 47(1): S89-S90. **IF_{2011}- 3.03**

313. Liu YH, Chen CC, Liao LL, Wan L, Tsai CH, Tsai FJ. Association of IL12B polymorphisms with susceptibility to Graves ophthalmopathy in a Taiwan Chinese population. *J Biomed Sci* 2012; 19;19:97. **IF_{2012} – 2.46**

314. Basu M, Das T, Ghosh A, et al. Gene-gene interaction and functional impact of polymorphisms on innate immune genes in controlling Plasmodium falciparum blood infection level. *PLoS One* 2012; 7(10):e46441 **IF_{2012} – 3.73**

315. Szperl A. Mapping complex and momogenetic disorders: methods and application. Doctoraat. Rijkuniversiteit Groningen. ISBN: 978-90-367-5721-8, 2012

316. Мария Христова Христова. Имуногенетични проучвания при системен лупус еритематозус и дерматомиозит. *Дисертация*, София 2014, стр. 36

317. Da Silva HA. Polimorphismos de base unica em genes de interleucinas no lupus eritematoso. *PhD thesis*, Programa de Pos-Graduacao em Genetica. Univeridade Federal de Pernambuco Centro de Ciencias Biologicas. Recife 2014

318. Paradowska-Gorycka A. U1-RNP and TLR receptors in the pathogenesis of mixed connective tissue disease Part I. The U1-RNP complex and its biological

significance in the pathogenesis of mixed connective tissue disease. *Reumatologia* 2015; 53, 2: 94–100

319. Agha-Hosseini F, MS Moosavi, MH Tabrizi. Comparison of Oral Lichen Planus and Systemic Lupus Erythematosus in Interleukins Level. *Archives of Iranian Medicine* 2015: 18(10). **IF_{2014}- 0.936**

320. Holanda FMC. Estudo da associação entre paracoccidioidomicose e os polimorfismos dos genes IL12B (posição 3'UTR+ 1188 A/C), IL12RB1 (posição 11014 A/G no éxon 7) e IFNG (posição +874T/A) 2015,Thesis, Universidade de Sao Paolo

321. Xiao JP, Wang XR, Zhang S, Wang HY, Ye L, Pan HF, Wang DG. Association between rs6887695 and 3'-untranslated region polymorphisms within the interleukin-12B gene and susceptibility to autoimmune diseases in Asian and European population: A meta-analysis. *Autoimmunity* 2016 Jun;49(4):277-84. doi: 10.3109/08916934.2016.1166215. Epub 2016 Apr 12. **IF_{2014}- 2.714**

322. Paradowska-Gorycka A., Sowinska B, M.K. Grobelna, M. Walczyk M. Olesinska, P. Piotrowski P.P. Jagodzinski. Genetic variants in IL-12B and IL-27 in the Polish patients with systemic lupus erythematosus. Scandinavian *Journal of Immunology*, 2016, DOI: 10.1111/sji.12439 **IF_{2014}-1.739**

323. Carvalho FMC, Busser FD, Freitas VLT, Furucho CR, Sadahiro A, et al. and Shikanai Yohuda. Polymorphisms on *IFNG*, *IL12B* and *IL12RB1* genes and paracoccidioidomycosis in the Brazilian population. *Infection, Genetics and Evolution*. 2016, 2016; 43:245-51, doi:10.1016/j.meegid.2016.05.025 **IF_{2014}-3.015**

324. Zhao Q, Qinglin Du, Fang Wei, Jianping Xie and Xiaojing Ma. An Infectious Disease–Associated *Il12b* Polymorphism Regulates IL-12/23 p40 Transcription Involving Poly(ADP-Ribose) Polymerase 1. *J Immunol*, February 20, 2017, 1601894; DOI: https://doi.org/10.4049/jimmunol.1601894 **IF_{2015}-4.985**

325. Gorial FI and al. Cytokine Genetic Polymorphism and the Risk of Systemic Lupus Erythematosus in a Sample of Iraqi Patients. *Iraqi Medical Journal* 2018; 61(2):164-171

326. Larosa M, Zen M, Gatto M, Jesus D, Iaccarino L, Ines L, Doria A. IL-12 and IL-23/Th17 axis in systemic lupus erythematosus. *Experimental Biology and Medicine*, January 2019, DOI:10.1177/1535370218824547 **IF_{2018}-2.413**

Цитирана статия (публикация № 55)

Gulubova M.V., J. R. Ananiev, T. I. Vlaykova, Y. Yovchev, V. Tsoneva, **I. M. MANOLOVA.** Role of dendritic cells in progression and clinical outcome of colon cancer. ***Int J Colorectale Disease*** 2012;27(2):159-69

Резултатите са цитирани от:

327. Wang N, Du X, Zang L, Song N, Yang T, Dong R, Wu T, He X, Lu J. Prognostic impact of Metadherin-SND1 interaction in colon cancer. *Mol Biol Rep* 2012; 39(12):10497-504. **IF_{2012} – 2.929**

328. Fuxe J, Karlsson MC. TGF-β-induced epithelial-mesenchymal transition: a link between cancer and inflammation. *Semin Cancer Biol* 2012; 22(5-6):455-61. **IF_{2012} - 6.475**

329. Senovilla L, Vacchelli E, Galon J, Adjemian S, Eggermont A, Fridman WH, Sautès-Fridman C, Ma Y, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. *Oncoimmunology* 2012; 1(8):1323-1343**.**

330. Xiao, W., Wu, K., Gong, W., Bo, P. Detection of CD1a+ positive dendritic cells and VEGF expression and their correlation in gastric carcinoma. *Chinese Journal of Clinical Oncology*. 2012; 39(21):1623-1625+1634

331. Linnebacher M. Tumor-infiltrating B cells come into vogue. *World J Gastroenterol* 2013; 19(1):8-11. **IF_{2013} – 2.457**

332. Orsini G, Legitimo A, Failli A, Ferrari P, Nicolini A, Spisni R, Miccoli P, Consolini R. Defective generation and maturation of dendritic cells from monocytes in colorectal cancer patients during the course of disease. *Int J Mol Sci* 2013; 14(11):22022-41. **IF_{2013} – 2.464**

333. Failli, A., Legitimo, A., Orsini, G., Romanini, A., Consolini, R. Numerical defect of circulating dendritic cell subsets and defective dendritic cell generation from monocytes of patients with advanced melanoma. *Cancer Letters* 2013; 337(2):184 – 192. **IF_{2013} - 4.258**

334. Liu, Y., Sæter, T., Vlatkovic, L., Servoll, E., Waaler, G., Axcrona, U., Giercksky, K.-E., Nesland, J.M., Suo, Z.-H., Axcrona, K. Dendritic and lymphocytic cell infiltration in prostate carcinoma. *Histology and Histopathology* 2013; 28(12):1621-1628. **IF_{2013} - 2.281**

335. Aerts, J.G., Hegmans, J.P. Tumor-specific cytotoxic t cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer. *Cancer Research* 2013 73 (8), pp. 2381-2388. **IF_{2013} - 8.65**

336. Oliveira MJ, S Velho. The Association between Inflammation and Colorectal Cancer. IN: Molecular Pathogenesis of Colorectal Cancer, 2013 – Springer

337. Orsini G**,** Legitimo A, Failli A, Ferrari P, Nicolini A, Spisni R, Miccoli P, Consolini R. Quantification of Blood Dendritic Cells in Colorectal Cancer Patients During the Course of Disease. *Pathol Oncol Res* 2014**;** 20(2):267-276. **IF_{2013} -1.555**

338. Okita, Y., Tanaka, H., Ohira, M., Muguruma, K., Kubo, N., Watanabe, M., Fukushima, W., Hirakawa, K. Role of tumor-infiltrating CD11b+ antigen-presenting cells in the progression of gastric cancer. *Journal of Surgical Research* 2014 186 (1), pp. 192-200. **IF_{2014} - 2.018**

339. Ni YH, Huang XF, Ding L, Wang ZY, Hu QG, Hou YY. Accumulation of CD208+ mature dendritic cells does not correlate with survival time in oral squamous cell carcinoma patients. *Journal of Oral and Maxillofacial Surgery* 2014; 72 (11):2178-2185. **IF_{2013} - 1.333**

340. Quinello C, Silveira-Lessa AL, Ceccon ME, Cianciarullo MA, Carneiro-Sampaio M, Palmeira P. Phenotypic differences in leucocyte populations among healthy preterm and full-term newborns. *Scand J Immunol* 2014; 80(1):57-70. **IF_{2013} - 2.199**

341. O'Toole, A, AJ Michielsen, B Nolan, M Tosetto. Tumour microenvironment of both early- and late-stage colorectal cancer is equally immunosuppressive. *British Journal of Cancer* 2014; 111(5): 927**. IF_{2013} - 5.082**

342. Omatsu M, Kunimura T, Mikogami T, Shiokawa A, Nagai T, Masunaga A, Kitami A, Suzuki T, Kadokura M. Difference in distribution profiles between CD163+ tumor-associated macrophages and S100+ dendritic cells in thymic epithelial tumors. *Diagn Pathol* 2014; 14;9(1):215. **IF_{2013} – 1.85**

343. Legitimo, A., Consolini, R., Failli, A., Orsini, G., Spisni, R. Dendritic cell defects in the colorectal cancer. *Human Vaccines and Immunotherapeutics* 2014; 10(11):3224-3235

344. Yanmei, J., Changfu, Z., Kai, C., et al. The clinical significance of dc-sign and dc-signr, which are novel markers expressed in human Colon Cancer. *PLoS ONE* 2014, 9 (12), e114748. **IF_{2013} – 3.73**

345. Jiang, Y., Lv, Z.-S., Zhang, Z.-G., Han, T. Relationship between dendritic cells, interleukin-23 and ulcerative colitis. *World Chinese Journal of Digestology* 2015; 23 (5):834-838

346. Wang Y, Bin Xu, Wen-Wei Hu, Lu-Jun Chen, Chang-Ping Wu, Bin-Feng Lu, Yue-Ping Shen, Jing-Ting Jiang. High expression of CD11c indicates favorable prognosis in patients with gastric cancer. *World J Gastroenterol* 2015; 21(31): 9403-12. / **IF_{2013} – 2.55**

347. Dheer R, JM Davies, MT Abreu. Inflammation and Colorectal Cancer. IN: - Intestinal Tumorigenesis, 2015 - Springer

348. O'Callaghan G, Houston A. Prostaglandin E2 and the EP receptors in malignancy: possible therapeutic targets? *Br J Pharmacol* 2015; 172(22): 5239-50. doi: 10.1111/bph.13331. **IF_{2014} – 4.842**

349. Malietzis G, Lee GH, Jenkins JT, Bernardo D, Moorghen M, Knight SC, Al-Hassi HO. Prognostic Value of the Tumour-Infiltrating Dendritic Cells in Colorectal Cancer: A Systematic Review. *Cell Commun Adhes* 2015; 22(1): 9-14. **IF_{2014} – 2.414**

350. Gomes JO, de Vasconcelos Carvalho M, Fonseca FP, Gondak RO, Lopes MA, Vargas PA. CD1a+ and CD83+ Langerhans cells are reduced in lower lip squamous cell carcinoma. *J Oral Pathol Med.* 2015 Dec 12. doi: 10.1111/jop.12389. **IF_{2014} – 1.926**

351. Lenos K, Goos JA, Vuist IM, den Uil SH, Delis-van Diemen PM, Belt EJ, Stockmann HB, Bril H, de Wit M, Carvalho B, Giblett S, Pritchard CA, Meijer GA, van Kooyk Y, Fijneman RJ, van Vliet SJ. MGL ligand expression is correlated to BRAF mutation and associated with poor survival of stage III colon cancer patients. *Oncotarget* 2015; 6(28): 26278-90. press **IF_{2014} – 6.359**

352. St-Onge D. Analyse de la valeur pronostique du contexte immunologique du cancer superficiel de la vessi. Thesese, 2016 Universite Laval, Québec, Canada

353. Becht E, NA Giraldo, C Germain, A de Reyniès et al. Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers. *Advances in Immunology* 2016;130:95-190. doi: 10.1016/bs.ai.2015.12.002 **IF_{2015} – 7.064**

354. Pryczynicz A, Cepowicz D, Zaręba K, Gryko M, Hołody-Zaręba J, Kędra B, Kemona A, Guzińska-Ustymowicz K. Dysfunctions in the Mature Dendritic Cells Are Associated with the Presence of Metastases of Colorectal Cancer in the Surrounding Lymph Nodes. *Gastroenterol Res Pract* 2016(3):1-5.2016:2405437.doi: 10.1155/2016/2405437. **IF_{2014} – 1.75**

355. Gomes JO, de Vasconcelos Carvalho M, Fonseca FP, Gondak RO, Lopes MA, Vargas PA. CD1a+ and CD83+ Langerhans cells are reduced in lower lip squamous cell carcinoma. *J Oral Pathol Med* 2016;45(6):433-9. doi: 10.1111/jop.12389. **IF_{2016} – 2.043**

356. Pryczynicz A, Dariusz Cepowicz, Konrad Zaręba, et al. Dysfunctions in the Mature Dendritic Cells Are Associated with the Presence of Metastases of Colorectal Cancer in the Surrounding Lymph Nodes. *Gastroenterology Research and Practice* 2016; 2016:2405437 https://doi.org/10.1155/2016/2405437. **IF_{2016} – 1.863**

357. Tauriello DVF, A Calon, E Lonardo, Batlle E. Determinants of metastatic competency in colorectal cancer. *Mol Oncol* 2017; 11: 97-119. doi:10.1002/1878-0261.12018 **IF_{2016} – 5.314**

358. Colangelo T, Polcaro G, Muccillo L, D'Agostino G, Rosato V, Ziccardi P, Lupo A, Mazzoccoli G, Sabatino L, Colantuoni V. Friend or foe? The tumour microenvironment dilemma in colorectal cancer. *Biochim Biophys Acta* 2017; 1867(1):1-18. doi: 10.1016/j.bbcan.2016.11.001. **SJR – 5.34**

359. Pellicioli ACA, Bingle L, Farthing P, Lopes MA, Martins MD, Vargas PA. Immunosurveillance profile of oral squamous cell carcinoma and oral epithelial dysplasia through dendritic and T-cell analysis. *J Oral Pathol Med* 2017; 46:928-933. https://doi.org/10.1111/jop.12597 **IF_{2016} – 2.043**

360. VYČÍTAL, Ondřej. Molekulárně biologické mechanismy progrese kolorektálního karcinomu ve vztahu k individualizované onkochirurgické léčbě. Plzeň, 2017. Dizertační práce. Univerzita Karlova, Lékařská fakulta v Plzni, Klinika chirurgická. Vedoucí práce Liška, Václav.

361. Shang F-M, Liu H-L. Fusobacterium nucleatum and colorectal cancer: A review. *World Journal of Gastrointestinal Oncology* 2018; 10(3):71-81. doi:10.4251/wjgo.v10.i3.71.

362. Agnihotri N, Bhatnagar A. Differential ratios of fish/corn oil ameliorated the colon carcinoma in rat by altering intestinal intraepithelial CD8(+) T lymphocytes, dendritic cells population and modulating the intracellular cytokines. *Biomed Pharmacother* 2018; 98:600-608. doi: 10.1016/j.biopha.2017.12.041. **IF_{2016} – 2.759**

363. Wang D, DuBois R. Role of prostanoids in gastrointestinal cancer. *Journal of Clinical Investigation*. 2018; 128(7):2732-2742. DOI:10.1172/JCI97953. **IF_{2017} – 13.251**

364. Leman JK, Sandford SK, Rhodes JL, Kemp RA. Multiparametric analysis of colorectal cancer immune responses. *World Journal of Gastroenterology*. 2018;24(27):2995-3005. doi:10.3748/wjg.v24.i27.2995. **IF_{2017} – 3.3**

365. Lee H, Lee HJ, Song IH, Bang WS, Heo SH, Gong G, Park IA. CD11c-Positive Dendritic Cells in Triple-negative Breast Cancer. *In Vivo.* 2018 Nov-Dec;32(6):1561-1569. doi: 10.21873/invivo.11415. **IF_{2017} – 1.116**

366. Wagner F, Hölig U, Wilczkowski F, et al. Neoadjuvant Radiochemotherapy Significantly Alters the Phenotype of Plasmacytoid Dendritic Cells and 6-Sulfo $LacNAc^{+}$ Monocytes in Rectal Cancer. *Front Immunol*. 2019;10:602, doi:10.3389/fimmu.2019.00602. **SJR – 2.803 Q1**

367. Yuan M, Zhang X, Zhang J, Wang K, Zhang Y, Shang W, Zhang Y, Cui J, Shi X, Na H, Fang D, Zuo Y, Ren S. DC-SIGN-LEF1/TCF1-miR-185 feedback loop promotes colorectal cancer invasion and metastasis. *Cell Death Differ*. 2019 Jun 19. doi: 10.1038/s41418-019-0361-2. **IF_{2018} – 8.0**

Цитирана статия (публикация № 57)

Tchernev G, Ananiev J, Cardoso JC, Wollina U, Verma SB, Patterson JW, Dourmishev LA, Tronnier M, Okamoto H, Mizuno K, Kanazawa N, Gulubova M, **MANOLOVA I**, Salaro C. Sarcoidosis and molecular mimicry - important etiopathogenetic aspects: current state and future directions. ***Wien Klin Wochenschr***. 2012;124(7-8):227-38

Резултатите са цитирани от:

368. Paštar Z, Radoš J, Pavić I, Kovačević S, Vukasović A, Milavec-Puretić V, Lipozenčić J. Palisaded neutrophilic and granulomatous dermatitis in association with subcutaneous nodular and systemic sarcoidosis. *Acta Dermatovenerol Croat* 2013; 21(4):245-9**. IF_{2013} – 0.481**

369. Tanimoto, Y., Kataoka, M. Sarcoidosis and malignancy. (2013) *Japanese Journal of Chest Diseases* 2013; 72(8):838-845.

370. Aghajanova, L., Jaffe, R.B., Herndon, C.N. Infiltrative neurosarcoidosis presenting as secondary amenorrhea: Case report and review of the literature. *Obstetrical and Gynecological Survey* 2013; 68 (6): 482-488. **IF_{2013} – 2.514**

371. Taş, B., Biyik Özkaya, D., Taşkin, B., Sar, M., Özdemirc, B. Generalized granuloma annulare associated with Borrelia burgdorferi infection and p83 gene-a potential relation to the phenomenon of molecular mimicry and heat-shock proteins? Case report. *Turkiye Klinikleri Dermatoloji* 2013; 23 (1):21-27.

372. Guarneri F, C Guarneri. Molecular mimicry in cutaneous autoimmune diseases *World J Dermatol* 2013; 2(4):36-43

373. Cho, S.J., Weiden, M.D., Lee, C.G. Chitotriosidase in the pathogenesis of inflammation, interstitial lung diseases and COPD. *Allergy Asthma Immunology Research* 2014; 7 (1), pp. 14-21 **IF_{2013} – 2.653**

374. Nakamura S, Hashimoto Y, Nishi K, Takeda K, Mizumoto T, Demitsu T, Iizuka H. High rate of cardiac sarcoidosis presenting with cutaneous plaque type sarcoidosis in 18F-fluorodeoxyglucose positron emission tomography-computed tomography: a case series**.** *J Med Case Rep*. 2014; 8(1):17

375. Zipse MM, Sauer WH. Cardiac sarcoidosis. *Curr Cardiol Rep* 2014 Aug;16(8):514.

376. Alempijeviü T, Sokiü-Milutinoviü A, Tonþev L, Pavloviü-Markoviü A, Djuanoviü S, Tomanoviü N, Druloviü J. Primary biliary cirrhosis and hepatic sarcoidosis – A case report. *Vojnosanit Pregl* 2014; 71(1): 83–86 **IF_{2013} - 0,21**

377. Cho SJ, Weiden MD, Lee CG. Chitotriosidase in the Pathogenesis of Inflammation, Interstitial Lung Diseases and COPD. *Allergy Asthma Immunol Res* 2015; 7(1):14-21. https://doi.org/10.4168/aair.2015.7.1.14

378. Tas B, Caglar A, Ozdemir B. Treatment with Doxycycline of Generalized Annular Elastolytic Giant Cell Granuloma Associated with Borrelia burgdorferi Infection. *The West Indian Medical Journal* 2015; 64(4):447-451. doi:10.7727/wimj.2014.090.

379. Willoughby JMT. Crohn's disease and sarcoidosis in siblings: follow-up of a published report with a new case and brief review of the literature. *Frontline Gastroenterol 2016; doi:10.1136/flgastro-2015-100666*

380. Muñoz-Ortiz E, E Arévalo-Guerrero, P Abad, JM Sénior. Sarcoidosis cardíaca. Estado del arte. *IATREIA* 2016; 29(4): 458-469.

381. Broos CE, Hendriks RW, Kool M. T-cell immunology in sarcoidosis: Disruption of a delicate balance between helper and regulatory T-cells. *Curr Opin Pulm Med* 2016; 22(5):476-83. doi: 10.1097/MCP.0000000000000303. **IF_{2016} – 2.884**

382. MEQL Verde, IV do Nascimento, TS Dantas. Oral sarcoid granuloma associated with discoid lupus erythematosus: Case report. *J Oral Diagnosis* 2017; 2(1) DOI: 10.5935/2525-5711.20170028

383. Wilden S, Lang B, Weidenthaler-Barth B, Grabbe S and Tuettenberg A. Acquired symmetric asymptomatic lesions at the inner corners of the eyes. *Journal der Deutschen Dermatologischen Gesellschaft* 2017; 15:342-344. doi:10.1111/ddg.13068 **IF_{2016} – 2.865**

384. Wilden S, Lang B, Weidenthaler-Barth B, Grabbe S and Tuettenberg A. Asymptomatische, erworbene symmetrische Läsionen am Augeninnenwinkel. *JDDG:* Journal der Deutschen Dermatologischen Gesellschaft 23017; 15: 842-844. doi:10.1111/ddg.13068_g **IF_{2016} – 2.865**

385. James WE, Koutroumpakis E, Saha B, Nathani A, Saavedra L, Yucel RM, Judson MA. Clinical Features of Extrapulmonary Sarcoidosis Without Lung Involvement. *Chest* 2018 Feb 14. pii: S0012-3692(18)30257-5. doi: 10.1016/j.chest.2018.02.003. **IF_{2016} – 6.044**

Цитирана статия (публикация № 58)
MANOLOVA I, Gerenova J, Ivanova M. Serum levels OF Transforming Growth Factor-β1 (TGF-β1) in patients with systemic lupus erythematosus and Hashimoto's thyroiditis. ***Eur Cytokine Netw***. 2013 Mar;24(1):69-74.

Резултатите са цитирани от:

386. Zhou TB, Zhao HL, Fang SL, Drumen GPC. Association of transforming growth factor-β1 T869C, G915C, and C509T gene polymorphisms with rheumatoid arthritis risk. *Journal of Receptor and Signal Transduction Research* 2014; 34(6):469-475 **IF_{2014} - 1.63**

387. Zimmermann-Górska, I. Osteopoikilosis associated with keloids formation, rheumatoid arthritis, myasthenia, Graves' disease and megaloblastic anaemia. *Reumatologia* 2014; 52(2):146-152

388. Li J, Wei F. Retrospective analysis of TGF-β 1 expression in patients with thyroidectomy. *Cancer Biomarkers* 2015; 15(5): 693-698 **IF_{2014} - 1.721**

389. L Huang, Q Lv, F Liu, T Shi, C Wen. A Systems Biology-Based Investigation into the Pharmacological Mechanisms of Sheng-ma-bie-jia-tang Acting on Systemic Lupus Erythematosus by Multi-Level Data Integration**.** *Scientific Reports 2015***;** 5: 16401 | DOI: 10.1038/srep16401 **IF_{2014} - 5.578**

390. Jakiela B, Iwaniec T, Plutecka H, Celinska-Lowenhoff M, Dziedzina S, Musial J. Signs of impaired immunoregulation and enhanced effector T-cell responses in the primary antiphospholipid syndrome. *Lupus* December 9, 2015 doi: 10.1177/0961203315618267 **IF_{2014} - 2.197**

391. Dong H, Wen-zhuang Shen, Yu-jing Yan, Ji-lin Yi, Lin Zhang. Effects of $BRAF^{V600E}$ mutation on Na^+/I^- symporter expression in papillary thyroid carcinoma**.** *Journal of Huazhong University of Science and Technology [Medical Sciences]* 2016; 36(1): 77-81. **IF_{2014} – 0.83**

392. Конович Е.А., Халиф И.Л., Широких К.Е., Шапина М.В. Трансформирующий фактор роста - ß1, 2, 3 и интерлейкин-6 в крови больных язвенным колитом с различной клинической и эндоскопической активностью. *Молекулярная Медицина* 2016;14(4):51-56.

393. Altay M, İ Ateş, FM Yılmaz, C Topçuoğlu. The role of circulating sTWEAK in the pathogenesis of Hashimoto's thyroiditis—a pilot study. *Endokrynologia Polska* 2016; 67(6):562-566 DOI: 10.5603/EP.a2016.0033 **IF_{2016} - 1.341**

394. Xiaoliang He, Yunlong Zhang, Ai Zhu et al. Suppression of interleukin 17 contributes to the immunomodulatory effects of adipose-derived stem cells in a murine model of systemic lupus erythematosus. *Immunologic Research* 2016; 64(5-6):1157-1167 **IF_{2016} – 2.905**

395. Safdari Vahid, Ebrahim Alijani, Maryam Nemati, Abdollah Jafarzadeh. Imbalances in T Cell-Related Transcription Factors Among Patients with Hashimoto’s Thyroiditis. *Sultan Qaboos University Med J* 2017; 17(2):174–180.

396. Zhou Yi, Huimei Chen, Li Liu, et al. CD74 Deficiency Mitigates Systemic Lupus Erythematosus–like Autoimmunity and Pathological Findings in Mice. *The Journal of Immunology* 2017, 198 (7) 2568-2577; DOI: 10.4049/jimmunol.1600028 **IF_{2016} – 4.856**

397. Wallace CH, Wu BX, Salem M, et al. B lymphocytes confer immune tolerance via cell surface GARP-TGF-β complex. *JCI Insight* 2018; 3(7):e99863. doi:10.1172/jci.insight.99863.

398. Barahona Correa JE, Franco Cortés MA, & Ángel Uribe J, Rodríguez Camacho, LS. (2018). Comparison of Plasma Cytokine Levels before and after Treatment with Rituximab in Patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus-Associated Polyautoimmunity. *Universitas Médica.* 59. 1-16. 10.11144/Javeriana.umed59-3.cyto.

399. Wu Q, Yang Q, Sun H. Collagen triple helix repeat containing-1: a novel biomarker associated with disease activity in Systemic lupus erythematosus *Lupus* 2018 Oct 18:961203318804877. doi: 10.1177/0961203318804877. **IF_{2018} – 2.969**

400. Fovet C, Stimmer L, Contreras V et all. Targeting MOG to skin macrophages prevents EAE in macaques through TGFβ-induced peripheral tolerance. *BioRxiv* 2019, [09 Mar 2019], DOI: 10.1101/571828

401. Kailashiya V, Singh U, Rana R, Singh NK, Dash D & Kailashiya J. (2019) Regulatory T Cells and Their Association with Serum Markers and Symptoms in Systemic Lupus Erythematosus and Rheumatoid Arthritis, *Immunological Investigations*, 2019; 48(1):64-78, DOI: 10.1080/08820139.2018.1527852 . **IF_{2018} – 2.588**

402. Raymond WD, GØ Eilertsen, J Nossent Principal component analysis reveals disconnect between regulatory cytokines and disease activity in Systemic Lupus Erythematosus. *Cytokine,* 2019; 114:67-73, https://doi.org/10.1016/j.cyto.2018.10.013. **IF_{2018} – 6.395**

403. Vorobjova T, Tagoma A, Oras A et al. Celiac disease in children, particularly with accompanying type 1 diabetes, is characterized by substantial changes in the blood cytokine balance, which may reflect inflammatory processes in the small intestinal mucosa. *Journal of Immunology Research* 2019(5):1-17 DOI: 10.1155/2019/6179243 **SJR – 1.352**

Цитирана статия (публикация № 59):
Gulubova M, **MANOLOVA I**, Ananiev J, Kyurkchiev D, Julianov A, Altunkova I. Relationship of TGF-beta1 and Smad7 expression with decreased dendritic cell infiltration in liver gastrointestinal cancer metastasis. ***APMIS***, 2013;121: 967-975

Резултатите са цитирани от:

404. Wang, L-Z, Zhang, L, Wang, L-L, Lu, Y, Chen, L, Sun, Y, Zhao, H-G, Song, L, Sun, L-R. Muramyl dipeptide and anti-CD10 monoclonal antibody immunoconjugate enhances anti-leukemia immunity of T lymphocytes. *APMIS* 2016; 124: 800– 804. **IF_{2016} – 1.795**

Цитирана статия (публикация № 60):
Stanilova SA, Ivanova MG, Karakolev IA, Stoilov RM, Rashkov RK, **MANOLOVA IM**. Association of +3179G/A insulin-like growth factor-1 receptor polymorphism and insulin-like growth factor-1 serum level with systemic lupus erythematosus**.** ***Lupus.*** 2013 Nov;22(13):1388-93.

Резултатите са цитирани от:

405. Gatford KL, Heinemann GK, Thompson SD, Zhang JV, Buckberry S, Owens JA, Dekker. GA, Roberts CT; SCOPE Consortium. Circulating IGF1 and IGF2 and

SNP genotypes in men and pregnant and non-pregnant women**.** *Endocr Connect.* 2014; 3(3):138-49.

406. Wang J, Song J, Meng Z. Association of IGF-1R gene polymorphism with systemic lupus erythematosus. *Medical Journal of Wuhan University* 2015; 36(2):285-288.

407. Wu T, Ding H, Han J, Arriens C, Wei C, Han W, Pedroza C, Jiang S, Anolik J, Petri M, Sanz I, Saxena R, Mohan C. Antibody array based proteomic screening of serum markers in systemic lupus erythematosus - a discovery study. *J Proteome Res.* 2016 May 23. **IF_{2016} – 4.268**

408. Yu Wang, Cuixia Gao, Tiankang Guo, Ruifei Yang, Feifei Shao, Wenjuan Ma, Limin Tian. Association of insulin-like growth factor-I receptor and -II receptor gene polymorphisms with osteoporosis in postmenopausal women of Han Chinese. *Int J Clin Exp Pathol* 2017;10(2):2100-2109 **IF_{2015}-1.581**

409. Liu L, Su L, Jingyi Yang, Huiyuan Li, Jingke Yang, Xinjian Liu, Yongping Song, Hu Zhou, Renchi Yang. Association of insulin-like growth factor-1 receptor polymorphism and insulin-like growth factor-1 plasma level with chronic immune thrombocytopenia in Chinese population. *Meta Gene* 2017;11:1–4 **IF_{2016} – 1.27**

410. Wang Yu , Guo Tian-kang , Liu Jing , Yang Rui-fei, Shao Fei-fei, Tian Li-min. Association of insulin-like growth factor 1 receptor gene rs2229765 polymorphism with osteoporosis in postmenopausal women. *Chinese Journal of Tissue Engineering Research* 2017 Vol.21, No.12 **SJR-0.102**

411. Waldron J, Reymond W, Eilersten G, Nossent J. Insulin-like growth factor-1 (IGF1) in systemic lupus erythematosus: relation to disease activity, organ damage and immunological findings. *Lupus*, 2018, 27:963-970, DOI:10.1177/0961203318756288 **IF_{2016}- 2.454**

412. Ding H, Wu T. Insulin-Like Growth Factor Binding Proteins in Autoimmune Diseases. *Frontiers in Endocrinology*. (2018). 9. 10.3389/fendo.2018.00499. **IF_{2017}= 3.519**

413. Smith TJ, Joseph A M J L Janssen; Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy, *Endocrine Reviews*, 2019, 40 (1):236–267, https://doi.org/10.1210/er.2018-00066 **IF_{2018}- 4.963**

414. Skarlis C, Nezos A, Mavragani CP, Koutsilieris M. The role of insulin growth factors in autoimmune diseases. *Ann Res Hosp*, 2019; 3:10, DOI:10.21037/arh.2019.03.02

Цитирана статия (публикация № 63)

MANOLOVA I, Ivanova M, Stoilov R, Rashkov R and Stanilova S. Association of single nucleotide polymorphism at position -308 of the tumor necrosis factor-alpha gene with ankylosing spondylitis and rheumatoid arthritis. ***Biotechnol Biotechnol Equip*** 2014; 28: 1108-1114.

Резултатите са цитирани от:

415. Wang NG, Wang DC, Bing-Yi Tan, Feng Wang, Ze-Nong Yuan. TNF-α and IL10 polymorphisms interaction increases the risk of ankylosing spondylitis in Chinese Han population. *Int J Clin Exp Pathol* 2015;8(11):15204-15209. **IF - 1.891**

416. Prieto Pérez RM. Búsqueda de marcadores genéticos predictores de respuesta a fármacos biológicos en el tratamiento de la psoriasis. 2015 - repositorio.uam.es Memoria que presenta Rocío Mª Prieto Pérez para optar al Grado de Doctor Universidad autónoma de Madrid Facultad de Medicina Departamento de Farmacología y Terapéutica

417. El-Tahan RR, Ahmed M. Ghoneim and Noha El-Mashad. TNF-α gene polymorphisms and expression. *SpringerPlus*, 2016, 5:1508, DOI: 10.1186/s40064-016-3197-y **IF_{2015} - 0.982**

418. Tian H, Yin L, Xia Y, Ding K, He X. Relation between TNF-α genetic polymorphism and primary lung cancer. *International Journal of Clinical and Experimental Medicine*, 2016, 9: 16540-16543. **IF_{2015} - 1.075**

419. Ma HJ, Qing-Feng Yin, Yin Wu, Ming-Hao Guo. TNF-α-308 polymorphism determines clinical manifestations and therapeutic response of ankylosing spondylitis in Han Chinese. *Medicina Clinica*, 2017 **IF_{2015} - 1.125**

420. Aita A. Genetics in TNF-TNFR pathway: a complex network causing spondyloarthritis and conditioning response to therapy. [Ph.D. thesis] 2017 Dipartimento di Medicina, University of Padova

421. Peng Y, Liu Y, Huang D et al. Association of TNF-α-308(G/A) and -238(G/A) polymorphisms with non-traumatic osteonecrosis of the femoral head risks: a meta-analysis. *International Orthopaedics*, 2018, *DOI:10.1007/s00264-018-3859-1*. **IF_{2015} - 2.52**

422. Sode J, Bank S, Vogel U, Andersen PS, Sørensen SB, Bojesen AB, Andersen MR, Brandslund I, Dessau RB, Hoffmann HJ, Glintborg B, Hetland ML, Locht H, Heegaard NH, Andersen V. Genetically determined high activities of the TNF-alpha, IL23/IL17, and NFkB pathways were associated with increased risk of ankylosing spondylitis. *BMC Med Genet*, 2018;19(1):165. doi: 10.1186/s12881-018-0680-z. **IF_{2015} - 1.913**

423. Xia Y, Liang Y, Guo S, et al Association between cytokine gene polymorphisms and ankylosing spondylitis susceptibility: a systematic review and meta-analysis *Postgraduate Medical Journal* Published Online First: 15 October 2018. doi: 10.1136/postgradmedj-2018-135665 **SJR-0.22**

424. Bai, R., Zhang, Y., Liu, W., Ma, C., Chen, X., Yang, J., & Sun, D. (2018). The Relationship of Ankylosing Spondylitis and Subclinical Atherosclerosis: A Systemic Review and Meta-Analysis. *Angiology*, November 29, 2018, https://doi.org/10.1177/0003319718814309 **IF_{2017}-3.022**

425. Fang B, Wang D, Zheng J, Wei Q, Zhan D, Liu Y, Yang X, Wang H, Li G, He W, Xu L. Involvement of tumor necrosis factor alpha in steroid-associated osteonecrosis of the femoral head: friend or foe? *Stem Cell Res Ther*. 2019;10(1):5. doi: 10.1186/s13287-018-1112-x

---

Цитирана статия (публикация № 66)

Ivanova Mariana, **Irena MANOLOVA**, Vladimira Boyadzhieva, Rumen Stoilov, Nedko Dimitrov, Nikolay Stoilov, Berengere Aubry-Rozier, Rasho Rashkov & Didier Hans. Relationship between physical function, disease activity, spinal mobility and bone parameters (trabecular bone score and bone mineral density) in ankylosing spondylitis patients. ***Biotechnology & Biotechnological Equipment*** 2015; 29(5):956-962.

Резултатите са цитирани от:

426. Мысин М.А., Дорогойкина К.Д., Акулова А.И., Гайдукова И.З., Ребров А.П. Фенотипы болезни Бехтерева - назад в будущее. Медицинские интернет-конференции. *Терапия/Внутренние болезни*. ID: 2016-03-8-A-6296

Цитирана статия (публикация № 67) :
Gerenova, J. **MANOLOVA, I**. and Stanilova,S. Impact of IL-10 and IL-12B single nucleotide polymorphisms on circulating cytokine level in development of Hashimoto's thyroiditis. ***Biotechnology & Biotechnological Equipment*** 2016, 22(48):1-9.

Резултатите са цитирани от:

427. Al-Nasiri MA, Ehab D. Salman, Ali H. Ad'hiah and Sarmad A. Al-Mashtah. What is the impact of IL12B+1188 single nucleotide polymorphism on IL-12 serum level of multiple sclerosis Iraqi patients? *Int. J. Adv. Res.* 4(9), 2276-2281. DOI: 10.21474/IJAR01/1718

Цитирана статия (публикация № 68) :
Ivanova M., I. **MANOLOVA**, M. Ganeva, R. Gancheva, R. Stoilov and S. Stanilova. Elevated serum levels of Th17-related cytokines in patients with ankylosing spondylitis. ***Journal of the Balkan Tribological Association*** 2016; 22(3): 2244–2257

Резултатите са цитирани от:

428. Popova, V., Vazhev, Z., & Geneva-Popova, M. Analysis of the serum levels of the cytokines TNF-α, RANKL, OPG and IL-6 in patients with acute coronary syndrome and inflammatory joint disease. *Knowledge International Journal* 2018, *24*(1), 23 - 26.

Цитирана статия (публикация № 69) :
Ananiev J, **MANOLOVA I**, Aleksandrova E, Guluboba M. Impact of TGF-β1 expression and -509C>T polymorphism in the TGF-β1 gene on the progression and survival of gastric cancer. ***Pol J Pathol*** 2017; 68(3):234-240

Резултатите са цитирани от:

429. Molaei F, MM Forghanifard, Y Fahim. Molecular Signaling in Tumorigenesis of Gastric Cancer. Iranian Biomedical Jornal 2018, 22(4): 217-230 DOI: 10.29252/ibj.22.4.217 **SJR – 0.574**

Цитирана статия (публикация № 70) :
MANOLOVA I, Miteva L, Ivanova M, Kundurzhiev T, Stoilov R, Stanilova S. The Synergistic Effect of TNFA and IL10 Promoter Polymorphisms on Genetic Predisposition to Systemic Lupus Erythematosus. ***Genetic Testing and Molecular Biomarkers***, 2018, DOI:10.1089/gtmb.2017.0169

Резултатите са цитирани от:

430. Rolandelli A et al. The IFNG rs1861494 Single Nucleotide Polymorphism Is Associated with Protection against Tuberculosis Disease in Argentina. *Genes* **2018**, *9*(1), 46; doi:10.3390/genes9010046 **IF_{2016}= 3.6**

431. PIMENTA TS. Análise genômica comparativa e os polimorfismos nos genes TNFA, IFNG IL6 e IL10 associados à expressão de citocinas na infecção por Plasmodium vivax no município do itaituba, *Tese (Doutorado)* - Programa de Pós-

graduação em Neurociências e Biologia celular (PPGNBC), Instituto de Ciências Biológicas, Universidade Federal do Pará, Belém, 2018.

432. Yuan Y, Wang X, Ren L, Kong Y, Bai J, Yan Y. Associations between interleukin-10 gene polymorphisms and systemic lupus erythematosus risk: a meta-analysis with trial sequential analysis. *Clin Exp Rheumatol*, 2019; 37(2):242-253. 0 **IF_{2017} – 3.201**

Цитирана статия (публикация № 71) :
Stanilova S, Stanilov N, Julianov A, **MANOLOVA I**, Miteva L. Transforming growth factor-β1 gene promoter -509C/T polymorphism in association with expression affects colorectal cancer development and depends on gender. ***PLoS One***. 2018 Aug 2;13(8):e0201775. doi: 10.1371/journal.pone.0201775.

Резултатите са цитирани от:

433. Lu X, C Gao, C Liu, J Zhuang, P Su, H Li and all. Identification of the key pathways and genes involved in HER2-positive breast cancer with brain metastasis. *Pathology - Research and Practice*, 2019, 152475, https://doi.org/10.1016/j.prp.2019.152475. **IF_{2017} – 1.466**

Цитирана статия (публикация № 73) :
Ivanova M, **MANOLOVA I**, Miteva L, Gancheva R, Stoilov R, Stanilova S. Genetic variations in the IL-12B gene in association with IL-23 and IL-12p40 serum levels in ankylosing spondylitis. ***Rheumatol Int.*** 2019, 39(1): 111-119, . doi:10.1007/s00296-018-4204-0

Резултатите са цитирани от:

434. Xu Zhang X, Lu J, Pan Z and all. DNA methylation and transcriptome signature of the IL12B gene in ankylosing spondylitis. *International Immunopharmacology*, 2019; 71:109-114, DOI: 10.1016/j.intimp.2019.03.026 **IF_{2017} – 3.118**

Цитирана статия (публикация № 76)
Геренова Ж.Б., **И.М. МАНОЛОВА.** Серумни нива на интерлевкин-18 и при пациенти с тиреоидит на Hashimoto. ***Ендокринология*** 2009, том XIV, бр.2:98-102.

Резултатите са цитирани от:

435. MEKOVA, R. et al. Предразполагащи фактори за развитие на тиреоиден автоимунитет; Factors predisposing to the development of thyroid autoimmunity / R. Mekova, M. Boyanov. // *Endokrinologiia*, 18, 2013, N 1, ISSN 1310-8131 , с. 41-51, 1 tabl. Sum. Bulg., Engl. 37 ref.

Цитирана статия (публикация № 78)
Иванова М., **И. МАНОЛОВА,** Р. Стоилов и К. Пеева. Влиянието на болестната активност и рентгенографската увреда на гръбнака върху физическата функция при анкилозиращ спондилит. ***Ревматология*** XVII, 2009, бр.4:26-32

Резултатите са цитирани от:

436. TROEV, T. et al. Физикална и рехабилитационна медицина в съвременните терапевтични методи за лечение на анкилозиращия спондилит; Physical and rehabilitation medicine in the contempory therapeutic methods of ankylosing spondylitis treatment / T. Troev, M. Georgieva, E. Konakchieva. // *Prevantivna meditsina*, 2, 2013, N 5, ISSN 1314-5681 , с. 28-33, Sum. Bulg., Engl. 22 ref.

Цитирана статия (публикация № 79)

Митева Л., **И. МАНОЛОВА**, М. Иванова, Р. Рашков, Р. Стоилов и С. Станилова. Липса на асоциация между промоторния полиморфизъм -1082A/G в гена за интерлевкин-10 и генетичното предразположение към системен lupus erythematosus. ***Ревматология*** XVIII, 2010, бр.3:33-38.

Резултатите са цитирани от:

437. Yin Q, Wu LC, Zheng L, Han MY, Hu LY, Zhao PP, Bai WY, Zhu XW, Xia JW, Wang XB, Zhang XW, Zheng HF. Comprehensive assessment of the association between genes on JAK-STAT pathway (IFIH1, TYK2, IL-10) and systemic lupus erythematosus: a meta-analysis. *Archives of Dermatological Research*. 2018; 10.1007/s00403-018-1858-0. **IF_{2017} - 2.148**

Цитирана статия (публикация № 81)

Иванова М, Р. Стоилов, **И. МАНОЛОВА**. Остеоартроза – патофизиология и фармакологични средства за лечение. ***Ревматология*** год. XVIII, 4, 2010, 15-21.

Резултатите са цитирани от:

438. ПЕТРОВА Н. „Роля на кинезитерапията за подобряване качеството на живот при пациенти с ревматоиден артрит”. ДИСЕРТАЦИЯ ЗА НАУЧНАТА И ОБРАЗОВАТЕЛНА СТЕПЕН " ДОКТОР", Благоевград, 2014

Цитирана статия (публикация № 82)

Иванова М., Р. Стоилов, М. Платиканова и **И. МАНОЛОВА**. Пилотно проучване на серумните нива на TNF-α във връзка с клиничните и лабораторните параметри на болестната активност при българска популация от болни с АС. ***Ревматология*** XIX, 2011, бр.2:25-30.

Резултатите са цитирани от:

439. TROEV, T. et al. Физикална и рехабилитационна медицина в съвременните терапевтични методи за лечение на анкилозиращия спондилит; Physical and rehabilitation medicine in the contempory therapeutic methods of ankylosing spondylitis treatment / T. Troev, M. Georgieva, E. Konakchieva. // *Prevantivna meditsina*, 2, 2013, N 5, ISSN 1314-5681 , с. 28-33, Sum. Bulg., Engl. 22 ref.

Цитирана статия (публикация № 87)

Gerenova Julieta B, **Irena M. Manolova**, Vania I. Tzoneva. Clinical significance of autoantibodies to parietal cells in patients with Hashimoto's thyroiditis. ***Follia Medica***, 2013, 55(2): 26-32.

Резултатите са цитирани от:

440. Rusak E, A Chobot, A Krzywicka, J Wenzlau. Anti-parietal cell antibodies – diagnostic significance. *Advances in Medical Sciences* 2016; 61(2):175–179 **SJR – 0.7**

441. Котелевец СМ, Хапаев БА Гендерные популяционные различия в распространенности атрофического гастрита с легкой, умереннойи тяжелой атрофией в обоих отделах желудка среди разных этнических групп. *Дневник Казанской Медицинской Школы* 2017; 2(16): 52-57

442. E Szczepanekparulska, A Hernik, M Ruchała. Anemia in thyroid diseases. *Pol. Arch. Intern. Med*, 2017; 127(5):352-360 **IF_{2016} - 2.309**

443. Duran ID, K Ağbaht, İ Soykan. Coexistence of Autoimmune and Allergic Diseases with Autoimmune Thyroid Diseases. *Turk J Endocrinol Metab* 2017; 21:120-126 **SJR – 0.11**

444. Utiyama, S.R.R., De Bem, R.S., Skare, T.L. et al. Anti-parietal cell antibodies in patients with autoimmune thyroid diseases. *J Endocrinol Invest* 2018; 41(5): 523-529, https://doi.org/10.1007/s40618-017-0755-2 **SJR - 1.072**

445. Лосик ЕА. Клинико-морфологическая характеристика аутоиммунного гастрита. Диссертация на соискание ученой степени кандидата медицинских наук. Москва, 2018

Цитирана статия (публикация № 89)

Gerenova J, Avramova A, **MANOLOVA I**, Stanilova S. Association of -1082 A/G promoter polymorphism of IL-10 gene and genetic predisposition to Hashimoto's thyroiditis. ***Endokrinologya***, 2013 18(2):71-80.

Резултатите са цитирани от:

446. Jung JH, Song GG, Kim J-H, Choi SJ. Association of interleukin 10 gene polymorphisms with autoimmune thyroid disease: Meta-analysis. Scandinavian Journal of Immunology, 2016, DOI: 10.1111/sji.12470 **IF_{2015} - 2.270**

Цитирана статия (публикация № 96) :

Koni Ivanova, **Irena MANOLOVA**, Maria-Magdalena Ignatova, Maya Gulubova Immunohistochemical Expression of TGF-B1, SMAD4, SMAD7, TGFβRII and CD68-Positive TAM Densities in Papillary Thyroid Cancer. ***Open Access Maced J Med Sci***, 2018; 6(3): 435–441. **SJR-0.199**

Резултатите са цитирани от:

447. Chernenko O. V., Sulaieva O. M., Chuba V. Ya., Ogryzko T. V., Larin O. S. Role of Macrophages in the Progression of Papillary Thyroid Carcinoma. *UDC* 616.441-006.04.-092-071(075.8) 2018 – Том 3, No 6 (15):188-192

448. Yeh SJ, Lin CY, Li CW, Chen BS. Systems Biology Approaches to Investigate Genetic and Epigenetic Molecular Progression Mechanisms for Identifying Gene

Expression Signatures in Papillary Thyroid Cancer. *International Journal of Molecular Science*, 20(10):2536 DOI: 10.3390/ijms20102536 **SJR_{2018}-1,312 Q1**

Цитирана статия (публикация № 105)
MANOLOVA I., L. Miteva, M. Ivanova, Vasilev G., S. Stanilova. Polymorphisms in TNFA and IL10 gene promoters and risk of rheumatoid arthritis in Bulgarian population. ***Trakia J of Science***, 2015; 13(Suppl 2):16-20.

Резултатите са цитирани от:

449. Liu, Q., Yang, J., He, H. et al. Associations between interleukin-10 olymorphisms and susceptibility to rheumatoid arthritis: a meta-analysis and meta-regression. *Clin Rheumatol* 2018, 37 (12):3229–3237 https://doi.org/10.1007/s10067-018-4329-2 **IF_{2017}-2.141**

Цитирана публикация № 107:
Manolova I, M. Ivanova and S. Stanilova. Gene polymorphisms of immunoregulatory cytokines Il-10 and TGF-β1 in systemic lupus erythematosus in "genes and autoimmunity – Intracellular signaling and Microbiome contribution"._Edited By: Spaska Stanilova ISBN 978-953-51-1028-6, Published: March 13, 2013, Publisher: InTech

Резултатите са цитирани от:

450. д-р Мария Христова Христова. "Имуногенетични проучвания при системен лупус еритематозус и дерматомиозит". ДИСЕРТАЦИЯ ЗА НАУЧНАТА И ОБРАЗОВАТЕЛНА СТЕПЕН " ДОКТОР", София 2014, стр. 24

451. Metawie SA, RM ElRefai, SS ElAdle, RMH Shahin. Transforming growth factor-β1 in systemic lupus erythematosus patients and its relation to organ damage and disease activity. *The Egyptian Rheumatologist 2015*; 37(4):S49-S54.

452. Mokhtar, Galila M.; El-beblawy, Nagham M.S.; Adly, Amira A.; Elbarbary, Nancy S.; Kamal, Tarek M.; Hasan, Esraa M. Cytokine gene polymorphism [tumor necrosis factor-alpha (–308), IL-10 (–1082), IL-6 (–174), IL-17F, 1RaVNTR] in pediatric patients with primary immune thrombocytopenia and response to different treatment modalities. *Blood Coagulation & Fibrinolysis*. 2016, 27:313-323 **IF_{2015} - 1.242**

453. Raymond WD, Eilertsen GØ, Nossent J. Principal component analysis reveals disconnect between regulatory cytokines and disease activity in Systemic Lupus Erythematosus, *Cytokine*, 2018, https://doi.org/10.1016/j.cyto.2018.10.013. **IF_{2017} - 3.514**

От забелязаните 453 цитата в пълен текст (на електронен носител) са представени 21 цитирания в международни списания с импакт фактор.